



2021 World Conference on Lung Cancer

SEPTEMBER 8-14, 2021 | WORLDWIDE VIRTUAL EVENT

PROGRAM

CONNECT WITH US



#WCLC21
wclc2021.IASLC.org

VIRTUAL



CONFERENCE

CONQUERING THORACIC CANCERS WORLDWIDE

IASLC WCLC 2021 Program

Table of Contents

Program

Day 1 Wednesday, September 8, 2021	5
Day 2 Thursday, September 9, 2021	15
Day 3 Friday, September 10, 2021	30
Day 4 Saturday, September 11, 2021	44
Day 5 Sunday, September 12, 2021	50
Day 6 Monday, September 13, 2021	61
Day 7 Tuesday, September 14, 2021	69

Posters

Featured Posters	81
Posters	98

For Sessions with Live Q&A:

Most presenters will be available to answer any questions during the live Q&A at the end of the session.

For Sessions without Live Q&A:

Most presenters will be available to answer any questions during the session via the Q&A chat box.

Day 1 | Wednesday, September 8, 2021

05:45 - 06:45 MTE01: Meet the Expert - Targeted Therapies and/or Immunotherapy

✗ NOT FOR CME CREDIT

ROOM: IASLC BOOTH VIA INDUSTRY HUB AND EXHIBIT HALL

Chair: Edgardo Santos, USA

Meeting will be hosted in Zoom. Limited Capacity

05:45 MTE01.01: Targeted Therapies and/or Immunotherapy

Luis Raez, USA

05:45 - 06:45 MTE02: Meet the Expert - Screening, Incidental Nodules, and Adjuvant Therapy for Early-Stage Lung Cancer

✗ NOT FOR CME CREDIT

ROOM: IASLC BOOTH VIA INDUSTRY HUB AND EXHIBIT HALL

Chair: Raymond Osarogiagbon, USA

Meeting will be hosted in Zoom. Limited Capacity

05:45 MTE02.01: Screening, Incidental Nodules, and Adjuvant Therapy for Early-Stage Lung Cancer

Paula Ugalde, Canada

07:00 - 08:00 PL01: Opening Plenary: Access and Disparities

(Japanese, Mandarin, Spanish Translation Available)

✓ IASLC CME ACCREDITED

ROOM: PROGRAM AUDITORIUM

Chair: Tetsuya Mitsudomi, Japan & Lucia Zatarain Barron, Mexico

07:00 PL01.01: Introduction and IASLC Award Presentations

07:30 PL01.02: Disparities in Lung Cancer Care Across the Population

Raymond Osarogiagbon, USA

07:40 PL01.03: Disparities in Lung Cancer Care: The Global Burden

Alex Adjei, USA

07:50 PL01.04: Live Discussion with Speakers

08:15 - 09:15**MA01: Multimodality Management of Advanced Lung Cancer** **IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Multimodality of Advanced Lung Cancer**

- 08:15 MA01.01: The Role of Surgery for M1a Non-Small-Cell Lung Cancer with Contralateral Lung Involvement**
Arvind Kumar, USA
- 08:20 MA01.02: Surgical Complexity of Pulmonary Resections Performed for Oligometastatic Non-Small Cell Lung Cancer**
Mara Antonoff, USA
- 08:25 MA01.03: PREC Multicentre Restrospective Study: A Preoperative Risk Classification for Synchronous Oligometastatic Non-Small Cell Lung Cancer**
Luca Bertolaccini, Italy
- 08:30 MA01.04: Discussant**
Linda Martin, USA
- 08:45 MA01.05: Sintilimab, SBRT and GM-CSF for Advanced NSCLC: Safety Run-in Results of a Prospective, Multicenter, Phase II Trial**
Jianjiao Ni, China
- 08:50 MA01.06: Effects of the Immunotherapy Era on Maintenance Outcomes in Advanced Nonsquamous NSCLC: Subgroup Analysis of ECOG 5508**
Bharathi Muthusamy, USA
- 08:55 MA01.07: Prognostic Value of STK11 & KRAS Mutations and irAE Incidence in Response to Immunotherapy in Hispanics: A Multicenter Analysis**
Fahmin Basher, USA
- 09:00 MA01.08: Discussant**
Karen Reckamp, USA

08:15 - 09:15**OA01: The Impact of COVID-19 on Patients with Lung Cancer****ROOM: PROGRAM AUDITORIUM****Track: Management of Lung Cancer in the Era of COVID-19****Chair: Enriqueta Felip, Spain**

- 08:15 OA01.01: Analysis of Lung Cancer Patients Receiving SARS-CoV-2 Vaccines Revealed a Minority Subset With Poor Antibody Responses Relative to Controls**
Jorge Gomez, USA
- 08:25 OA01.02: Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study**
Luca Cantini, Italy
- 08:35 OA01.03: Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience**
Lucie Hijmering-Kappelle, Netherlands
- 08:45 OA01.04: Discussant**
Suresh Ramalingam, USA
- 08:55 OA01.05: Live Discussion with Speakers**

08:15 - 09:15 OA02: Contemporary Approaches to Supportive Care**ROOM: PROGRAM AUDITORIUM****Track: Palliative and Supportive Care****Chair: Grace Yang, Singapore**

- 08:15 OA02.01: Assessment of Patient-Reported Outcomes in Lung cancer Patients Treated with Thoracic Radiation**
Li Yang, China
- 08:25 OA02.02: Development of Machine Learning Model to Estimate Overall Survival in Patients with Advanced NSCLC and ECOG-PS > 1**
Mateus Cunha, Brazil
- 08:35 OA02.03: Medical Assistance in Dying (MAiD) in Patients With Lung Cancer**
Sara Moore, Canada
- 08:45 OA02.04: Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion-Positive NSCLC**
Kenji Kawasumi, Japan
- 08:55 OA02.05: Discussant**
Monica Malec, USA
- 09:05 OA02.06: Live Discussion with Speakers**

09:30 - 10:30 MA02: RET and Novel Combinations of Osimertinib**ROOM: PROGRAM AUDITORIUM****Track: Novel Therapeutics and Targeted Therapies**

- 09:30 MA02.01: Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial**
Shun Lu, China
- 09:35 MA02.02: Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer**
Qing Zhou, China
- 09:40 MA02.03: MET-Driven Acquired Resistance (AR) in Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)**
Sai-Hong Ou, USA
- 09:45 MA02.04: Discussant**
Shengxiang (Harry) Ren, China
- 10:00 MA02.05: A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib**
Satoru Miura, Japan
- 10:05 MA02.06: Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC**
Li Zhang, China
- 10:10 MA02.07: T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial**
Merel Jebbink, Netherlands
- 10:15 MA02.08: Discussant**
Adrian Sacher, Canada

09:30 - 10:30 OA03: Novel Approaches to Cessation in Cancer Care**ROOM: PROGRAM AUDITORIUM****Track: Risk Reduction and Tobacco Control****Chair: Matthew Steliga, USA**

- 09:30 OA03.01: Implementation of an Opt-Out Smoking Cessation Service for Oncology Patients**
Michael Cummings, USA
- 09:40 OA03.02: Tobacco Cessation Among Patients Undergoing Lung Cancer Screening: Success with Repetition**
April Plank, USA
- 09:50 OA03.03: Patient Factors Associated With Engagement of an Academic Institution Tobacco Cessation Referral Program**
Sarah Westergaard, USA
- 10:00 OA03.04: Discussant**
Lawson Eng, Canada
- 10:10 OA03.05: Live Discussion with Speakers**

09:30 - 10:30 OA04: Improving Thoracic Oncology Patient Outcomes**ROOM: PROGRAM AUDITORIUM****Track: Nursing and Allied Health Professionals****Chair: Zoe Merchant, UK**

- 09:30 OA04.01: Preconditioning with Move for Surgery Shortens Hospital Stay after Lung Cancer Surgery**
Yogita S. Patel, Canada
- 09:40 OA04.02: Diaphragm and Phrenic Nerve Preservation During Lung-Sparing Surgery for Malignant Pleural Mesothelioma: The Impact on Patient Outcomes**
Melissa Culligan, USA
- 09:50 OA04.03: Feasibility of Prospective Dietetic Assessment and Intervention of Patients Receiving Chemo-Radiotherapy for Lung Cancer**
Catherine Samuelson, UK
- 10:00 OA04.04: Discussant**
Carolyn Peddle-McIntyre, Australia
- 10:10 OA04.05: Live Discussion with Speakers**

10:45 - 11:45**MA03: Biomarkers for Immunotherapy: Are All Relevant?** IASLC CME ACCREDITED**ROOM: PROGRAM AUDITORIUM****Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)**

- 10:45 MA03.01: EPICAL Trial. A Phase Ib Study Combining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer**
Silvia Garcia-Roman, Spain
- 10:50 MA03.02: TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors**
Edward Garon, USA
- 10:55 MA03.03: NBTXR3 Activated by SBRT Combined with Nivolumab or Pembrolizumab in Patients With Advanced Cancers: Phase I Trial**
Colette Shen, USA
- 11:00 MA03.04: Discussant**
Giannis Mountzios, Greece
- 11:15 MA03.05: DNA Damage Response (DDR) Gene Mutations and Correlation With Immunotherapy Response in NSCLC Patients**
Jiaqing Liu, China
- 11:20 MA03.06: ctDNA Mass-Adjusted bTMB as a Predictive Biomarker in NSCLC Patients Receiving PD-(L)1 Inhibitors**
Wei Nie, China
- 11:25 MA03.07: Interferon-Gamma Mediated Immune Evasion: A Potential Mechanism of Resistance to Immunotherapy in Non-Small Cell Lung Cancer**
Fasheng Li, China
- 11:30 MA03.08: Discussant**
Solange Peters, Switzerland

10:45 - 11:45 **MA04: Current Status and Future Prospects of Pleural Mesothelioma and Thymoma**



ROOM: PROGRAM AUDITORIUM

Track: Mesothelioma, Thymoma and Other Thoracic Malignancies

- 10:45 MA04.01: Multimodality Treatment and Outcome in Stage III Thymic Epithelial Tumors (TETs): A Retrospective Analysis From the French RYTHMIC Network**
Jose Carlos Benítez, France
- 10:50 MA04.02: Characteristics of Genomic Alterations in Chinese Patients with Thymic Epithelial Tumors**
Xinglong Fan, China
- 10:55 MA04.03: A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17-21)**
Hyun Ae Jung, Korea
- 11:00 MA04.04: Discussant**
Paul Baas, Netherlands
- 11:15 MA04.05: Survival Benefit of Multiagent Chemotherapy With and Without Curative Surgery for Malignant Pleural Mesothelioma**
Ahmed Alnajar, USA
- 11:20 MA04.06: MicroRNAs Contribute to the Chemotherapy Response of Malignant Pleural Mesothelioma**
Michaela Kirschner, Switzerland
- 11:25 MA04.07: Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection**
Susana Cedres, Spain
- 11:30 MA04.08: Discussant**
Francoise Galateau-Salle, France

10:45 - 11:45 OA05: Palliative Care Service Models **IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Palliative and Supportive Care****Chair: Maria Ftanou, Australia**

- 10:45 **OA05.01: Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With an Advanced Thoracic Malignancy**
Kelly Gast, USA
- 10:55 **OA05.02: Acceptability of Automatic Referrals to Supportive and Palliative Care, by Patients Living with Advanced Lung Cancer: A Co-Design Process**
Desiree Hao, Canada
- 11:05 **OA05.03: Onco-Pall Clinic: An Embedded Care Model for Thoracic Malignancy**
Julia Agne, USA
- 11:15 **OA05.04: Discussant**
Brian Le, Australia
- 11:25 **OA05.05: Live Discussion with Speakers**

12:00 - 13:00 IS01: Industry Symposium Sponsored by Mirati Therapeutics: Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC **NOT FOR CME CREDIT****ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB**

- 12:00 **IS01.01: Welcome and Introduction**
Pasi Janne, USA
- 12:05 **IS01.02: Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC**
Suresh Ramalingam, USA
- 12:20 **IS01.03: Targeting Checkpoint Inhibitor Resistance in NSCLC**
Solange Peters, Switzerland
- 12:35 **IS01.04: Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-Driven NSCLC**
Pasi Janne, USA
- 12:50 **IS01.05: Live Q&A**

12:00 - 13:00 **IS02: Satellite CME Symposium by Med Learning Group: A New Era of Treatment Opportunities for Small-Cell Lung Cancer in the Second Line: An Innovative 3D View**

 CME ACCREDITED BY OTHER PROVIDER

ROOM: PROGRAM AUDITORIUM

- 12:00 **IS02.01:** Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer
- 12:15 **IS02.02:** Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC
- 12:30 **IS02.03:** Applying National Cancer Center Network (NCCN) Guidelines to Practice
- 12:45 **IS02.04:** Conclusions
- 12:50 **IS02.05:** Live Q&A

12:00 - 13:00 **IS03: Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects**

 CME ACCREDITED BY OTHER PROVIDER

ROOM: PROGRAM AUDITORIUM

- 12:00 **IS03.01:** Welcome and Introductions
- 12:05 **IS03.02:** EGFR Insertion Mutations in NSCLC: Why and How Do We Test?
Shirish Gadgil, USA
- 12:20 **IS03.03:** New and Emerging Therapies with exon20ins Mutations
Tony Mok, Hong Kong
- 12:40 **IS03.04:** Managing Toxicity with EGFR-Directed Therapies
Antonio Passaro, Italy
- 12:50 **IS03.05:** Audience Q&A and Closing Remarks

Day 2 | Thursday, September 9, 2021

05:15 - 06:15 **IS04: Industry Symposium Sponsored by AstraZeneca: Redefining the Treatment Journey in NSCLC with Immuno-oncology and EGFR-TKIs**

✗ NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 05:15 **IS04.01: Welcome and Introduction**
Yi-Long Wu, China
- 05:20 **IS04.02: Clinical Data with Immuno-oncology for Unresectable Stage III NSCLC**
Suresh Senan, Netherlands
- 05:35 **IS04.03: Translating the Clinical Benefits of EGFR-TKIs across EGFRm NSCLC**
Zhijie Wang, China
- 06:00 **IS04.04: Panel Discussion: Survivorship in NSCLC**

05:15 - 06:15 **MTE03: Meet the Expert - Mentorship for Established Thoracic Oncology Professionals**

✗ NOT FOR CME CREDIT

ROOM: IASLC BOOTH VIA INDUSTRY HUB AND EXHIBIT HALL

Chair: Jamal Khader, Jordan
Meeting will be hosted in Zoom. Limited Capacity

- 05:15 **MTE03.01: Mentorship for Established Thoracic Oncology Professionals**
Nan Wu, China

05:15 - 06:15 **MTE04: Meet the Expert - Thoracic Cancers Research and Resource Disparities among Geographic Regions**

✗ NOT FOR CME CREDIT

ROOM: IASLC BOOTH VIA INDUSTRY HUB AND EXHIBIT HALL

Chair: Laura Mezquita, Spain
Meeting will be hosted in Zoom. Limited Capacity

- 05:15 **MTE04.01: Thoracic Cancers Research and Resource Disparities among Geographic Regions**
David Harpole, USA

06:30 - 08:00 **PL02: Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)**



IASLC CME ACCREDITED

ROOM: PROGRAM AUDITORIUM

Track: Immunotherapy (Phase II/III Trials)

Chairs: David Harpole, USA & Tetsuya Mitsudomi, USA

- 06:30 PL02.01: Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study**
Melissa Johnson, USA
- 06:40 PL02.02: Discussant**
Julie Brahmer, USA
- 06:47 PL02.03: Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial**
Luis Paz-Ares, Spain
- 06:57 PL02.04: Discussant**
Charles Rudin, USA
- 07:04 PL02.05: IMpower010: Characterization of Stage IB-IIIa NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab**
Nasser Altorki, USA
- 07:14 PL02.06: Discussant**
Ichiro Yoshino, Japan
- 07:21 PL02.07: Global Variability in Lung Cancer Deaths Attributable to Air Pollution**
Christine Berg, USA
- 07:31 PL02.08: Discussant**
Joachim Aerts, Netherlands
- 07:38 PL02.09: International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials**
Matthew Smeltzer, USA
- 07:48 PL02.10: Discussant**
Marina Chiara Garassino, USA
- 07:55 PL02.11: Live Discussion with Speakers**

08:15 - 09:15 **MA05: Using Real World and Patient Reported Data to Identify Gaps and Needs for People with Lung Cancer: Impacts of the COVID-19 Pandemic, Treatment Patterns, and Psychosocial Impacts**

 **IASLC CME ACCREDITED**

ROOM: PROGRAM AUDITORIUM

Track: Patient Advocacy

- 08:15** **MA05.01: Patients' Experiences During COVID-19: Insights from The Second Global Lung Cancer Coalition Patient Experience Survey**
Jackie Fenemore, UK
- 08:20** **MA05.02: Impact of Covid-19 on Lung Cancer Care and Utilization of Patient Support Resources**
Rashmi Acharya, USA
- 08:25** **MA05.03: Considering the Continued Impact of the COVID-19 Pandemic on Patient Advocacy and Support Organisations**
Matthew Peters, Australia
- 08:30** **MA05.04: Discussant**
Anne-Marie Baird, Ireland
- 08:45** **MA05.05: Treatment Patterns in Patients With EGFR-Positive Lung Cancer: A Real-World Patient-Report**
Ivy Elkins, USA
- 08:50** **MA05.06: The Psychosocial Impact of Lung Cancer – A European Perspective**
Anne-Marie Baird, Switzerland
- 08:55** **MA05.07: Discussant**
Jennifer King, USA

08:15 - 09:15 OA06: Prognosis and Staging**ROOM: PROGRAM AUDITORIUM****Track: Staging/Pulmonary Medicine****Chair: Ann Leung, USA**

- 08:15 OA06.01: Validation of the 8th Ed TNM: Invasive Size for Pathologic T Descriptor in Stage I-IIA Resected Nonmucinous Adenocarcinomas**
Yan Li, USA
- 08:25 OA06.02: High-Grade Patterns Cause the Upstaging of Lung Adenocarcinomas From T1 to T2a: A Multicentric Analysis**
Pietro Bertoglio, Italy
- 08:35 OA06.03: PL1/2 Status is Associated With Worse Survival in T2 Non-Small Cell Lung Carcinoma: Is There A Need for a New Subgroup in the T Classification?**
İsmail Sarbay, Turkey
- 08:45 OA06.04: Constructing a Global Molecular Database for Thoracic Malignancies: The IASLC Molecular Subcommittee Lung Cancer Dataset**
Raymond Osarogiagbon, USA
- 08:55 OA06.05: Discussant**
Jorge Alatorre, Mexico
- 09:05 OA06.06: Live Discussion with Speakers**

08:15 - 09:15 OA07: What's On The Horizon for SCLC?**ROOM: PROGRAM AUDITORIUM****Track: Small Cell Lung Cancer/ NET****Chair: Christine Lovly, USA**

- 08:15 OA07.01: Signatures of Plasticity and Immunosuppression in a Single-Cell Atlas of Human Small Cell Lung Cancer**
Joseph Chan, USA
- 08:25 OA07.02: Phenotypic Transition Contributes to Small Cell Lung Cancer Metastasis Through SWI/SNF Complex-Induced TAZ Silencing**
Yujuan Jin, China
- 08:35 OA07.03: A Phase II Study of Frontline Rucaparib + Nivolumab in Platinum Sensitive ES SCLC: Interim Analysis**
Aman Chauhan, USA
- 08:45 OA07.04: Discussant**
Anne Chiang, USA
- 08:55 OA07.05: Live Discussion with Speakers**

09:30 - 10:30 MA06: Differentiating Outcomes and Impact in Unresectable NSCLC**ROOM: PROGRAM AUDITORIUM****Track: Locally Advanced Non-Small Cell Lung Cancer**

- 09:30 MA06.01: Death From Intercurrent Disease After Proton- Versus Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer**
Nikhil Yegya-Raman, USA
- 09:35 MA06.02: Impact of Heart and Lung Radiation Dose and Lymphopenia on Non-Small Cell Lung Cancer Outcomes**
Jessica Little, UK
- 09:40 MA06.03: Deep Learning-Based Survival Prediction for Non-Small Cell Lung Cancer Patients Undergoing Radical Radiotherapy**
Bilal Tahir, UK
- 09:45 MA06.04: Discussant**
Megan Daly, USA
- 10:00 MA06.05: Patterns of Care in Maintenance Therapy in U.S. Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC)**
Jason Liu, USA
- 10:05 MA06.06: Treatment Recommendations for Stage III NSCLC by 3 Dutch Multidisciplinary Tumor Boards Prior To, and Following the PACIFIC Trial**
Merle Ronden, Netherlands
- 10:10 MA06.07: Inferior Outcomes in Minority Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC) After Durvalumab Consolidation Therapy**
Franco Dickson, USA
- 10:15 MA06.08: Discussant**
Jyoti Patel, USA

09:30 - 10:30 OA08: Moving Beyond New Drugs: What Else Matters?**ROOM: PROGRAM AUDITORIUM****Track: Health Services Research/Health Economics****Chair: Upal Roy, USA**

- 09:30 OA08.01: Trends in Within-Class Changes in US Prices of Drugs used for Metastatic Non-Small Cell Lung Cancer from 2015 to 2020**
Aakash Desai, USA
- 09:40 OA08.02: First Line Treatment Patterns in Advanced NSCLC Patients With Compromised Performance Status or Comorbidities**
Julia Judd, USA
- 09:50 OA08.03: The 5-year Survival Rate of Postoperative Non-small Cell Lung Cancer Patients with Two Different Follow-up Patterns**
Daqiang Sun, China
- 10:00 OA08.04: Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population**
Marie-pier Gauthier, Canada
- 10:10 OA08.05: Discussant**
Clarissa Baldotto, Brazil
- 10:20 OA08.06: Live Discussion with Speakers**

09:30 - 10:30 OA09: Expanding Immunotherapy Options for Non-small Cell Lung Cancers**ROOM: PROGRAM AUDITORIUM****Track: Immunotherapy (Phase II/III Trials)****Chairs: Rina Hui, Australia**

- 09:30 OA09.01: First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA**
David Carbone, USA
- 09:40 OA09.02: Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases**
Ernest Nadal, Spain
- 09:50 OA09.03: Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)**
Shirish Gadgeel, USA
- 10:00 OA09.04: Discussant**
Charu Aggarwal, USA
- 10:10 OA09.05: Live Discussion with Speakers**

10:45 - 11:45

MA07: Liquid Biopsy Applications for Immuno-oncology, Targeted Therapies, and Early Stage NSCLC**IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities**

- 10:45 MA07.01: Dynamic Liquid Biopsy During Immunotherapy Anticipates Hyperprogression And Early Death in Advanced Non-Small Cell Lung Cancer**
Laura Bonanno, Italy
- 10:50 MA07.02: Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150**
Martin Reck, Germany
- 10:55 MA07.03: Paired Liquid and Tissues Biopsies to Guide Treatment for Patients That Progress on 2nd Line Osimertinib Treatment**
J.W.T. van der Wel, Netherlands
- 11:00 MA07.04: Discussant**
Julia Rotow, USA
- 11:15 MA07.05: A Novel Blood-Based microRNA Diagnostic Test With Very High Accuracy for Early Lung Cancer Screening and Monitoring**
Andrew Zhang, USA
- 11:20 MA07.06: Circulating Tumor DNA for Monitoring Minimal Residual Disease and Early Detection of Recurrence in Early Stage Lung Cancer**
Aaron Tan, Singapore
- 11:25 MA07.07: High Sensitivity of Detecting Stage I Lung Cancer Using Genome-wide Multi-dimensional Fragmentomic Profiles of Cell Free DNA**
Wei Guo, China
- 11:30 MA07.08: Discussant**
Chris Abbosh, UK

10:45 - 11:45**OA10: Improving Care for People with Lung Cancer: Biomarker Testing Access, Psychosocial Distress, Care Navigation, and COVID-19 Vaccination****IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Patient Advocacy****Chair: Andrew Ciupek, USA**

- 10:45** **OA10.01: Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer: A Mixed-Methods Survey of Us-Based Oncology Clinicians**
Leigh Boehmer, USA
- 10:55** **OA10.02: Psychosocial Distress in Patients with Driver-Mutant Lung Cancer**
Lia Head, USA
- 11:05** **OA10.03: How LungMATCH, A Personalized Treatment Navigation and Clinical Trial Matching Service, Affects the Treatment Journey**
Daniel Saez, USA
- 11:15** **OA10.04: COVID-19 Vaccine Acceptance and Communications Effectiveness Amongst Canadian Lung Cancer Patients.**
Christina Sit, Canada
- 11:25** **OA10.05: Discussant**
Joshua Sabari, USA
- 11:35** **OA10.06: Live Discussion with Speakers**

10:45 - 11:45**OA11: Early Stage NSCLC****IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Early Stage/Localized Disease/Ablative Therapies****Chair: Jae Kim, USA**

- 10:45** **OA11.01:** Neoadjuvant Pembrolizumab for Early Stage Non-Small Cell Lung Cancer
Jair Bar, Israel
- 10:55** **OA11.02:** Treatment Outcomes of Re-irradiation Using Stereotactic Ablative Radiotherapy to Lung: A Propensity Score Matching Analysis
Tae Hoon Lee, Korea
- 11:05** **OA11.03:** Survival and Prognostic Factors of Resected T3N0M0 NSCLC
Edouard Marques, Canada
- 11:15** **OA11.04:** Impact of Local Control on Cause-Specific Survival After SBRT for Early-Stage NSCLC: Dynamic Prediction With Landmarking
Kazuhito Ueki, Japan
- 11:25** **OA11.05:** Discussant
Pamela Samson, USA
- 11:35** **OA11.06:** Live Discussion with Speakers

12:00 - 13:00 MA08: Driver Mutations and Immune Profiles in Early Stage NSCLC**ROOM: PROGRAM AUDITORIUM****Track: Early Stage/Localized Disease/Ablative Therapies**

- 12:00 MA08.01: Presence of High-Grade Subtype Predicts Recurrence of Stage I Lung Adenocarcinoma Only in EGFR-Mutated Patients**
Junji Ichinose, Japan
- 12:05 MA08.02: Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort**
Sabine Schmid, Canada
- 12:10 MA08.03: Adjuvant Chemotherapy for Patients with High-Risk Stage I Lung Adenocarcinoma Stratified by Epidermal Growth Factor Receptor Mutation Status**
Yasuhiro Tsutani, Japan
- 12:15 MA08.04: Discussant**
Els Wauters, Netherlands
- 12:30 MA08.05: Integrating Genomic and Transcriptomic Features Predict the Recurrence Risk of Stage IA Non-Small Cell Lung Cancer**
Shirong Zhang, China
- 12:35 MA08.06: Immune Cell Profiles as Predictors of Survival in Surgically Treated Non-Small Cell Lung Cancer (NSCLC)**
Laura Sellmer, Germany
- 12:40 MA08.07: Immune Characteristics Associated With Lymph Node Metastasis in Early-Stage NSCLC Discovered via T Cell Receptor Repertoires Sequencing**
Min Li, China
- 12:45 MA08.08: Discussant**
Keiju Aokage, Japan

12:00 - 13:00 **OA12: Understanding and Augmenting Responses to Immunotherapy for Thoracic Malignancies**



ROOM: PROGRAM AUDITORIUM

Track: Tumor Biology and Systems Biology: Basic and Translational Science

Chairs: Valsamo Anagnostou, USA

- 12:00 **OA12.01: Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma**
Valsamo Anagnostou, USA
- 12:10 **OA12.02: Metformin has Divergent Effects on the Tumor Immune Microenvironment of Non-Small Cell Lung Cancer (NSCLC) Depending on Obesity**
Joseph Barbi, USA
- 12:20 **OA12.03: Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC**
Shuai Li, USA
- 12:30 **OA12.04: Pre-Treatment T-Cell Receptors (TCR) Repertoire in Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Single Agent Immunotherapy**
Afaf Abed, Australia
- 12:40 **OA12.05: Discussant**
David Carbone, USA
- 12:50 **OA12.06: Live Discussion with Speakers**

13:15 - 14:15 **IS05: Advancing the Lung Cancer Landscape with Novel Strategies**



ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 13:15 **IS05.01: Welcome and Introductions**
David Gandara, USA
- 13:20 **IS05.02: The Evolving Biomarker Landscape in Advanced NSCLC**
David Gandara, USA
- 13:35 **IS05.03: KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC**
Alexander Spira, USA
- 13:50 **IS05.04: Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC**
Afshin Dowlati, USA
- 14:05 **IS05.05: Discussion**

13:15 - 14:15 **IS06: Industry Symposium Sponsored by Jazz Pharmaceuticals: Exploring a Treatment Option for Patients with Previously Treated Metastatic Small Cell Lung Cancer (SCLC)**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 13:15 IS06.01: An Overview of Unmet Needs in SCLC**
Eric Nadler, USA
- 13:30 IS06.02: Current Treatment Guidelines for SCLC**
Eric Nadler, USA
- 13:45 IS06.03: Efficacy and Safety Findings from a Study of an FDA-Approved Treatment for Previously Treated Metastatic SCLC**
Eric Nadler, USA
- 14:00 IS06.04: Considerations for Dosing, Administration, and Patient Counseling**
Eric Nadler, USA

13:15 - 14:15 **IS07: Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC**

 CME ACCREDITED BY OTHER PROVIDER

ROOM: PROGRAM AUDITORIUM

- 13:15 IS07.01: Introduction**
Roy Herbst, USA
- 13:20 IS07.02: Key Concepts in NSCLC Biomarker Testing**
Aleš Ryška, Czech Republic
- 13:35 IS07.03: Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC**
Roy Herbst, USA
- 13:55 IS07.04: IRAE Considerations for Patients with NSCLC Receiving Immunotherapy**
Sarah Goldberg, USA
- 14:05 IS07.05: Live Q&A**

14:30 - 16:00 PL02A: Plenary 2: Presidential Symposium (Rebroadcast)*(Japanese, Mandarin, Spanish Translation Available)***IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Immunotherapy (Phase II/III Trials)****Chairs: David Harpole, USA & Tetsuya Mitsudomi, Japan**

- 14:30 PL02A.01: Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study**
Melissa Johnson, USA
- 14:40 PL02A.02: Discussant**
Julie Brahmer, USA
- 14:47 PL02A.03: Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial**
Luis Paz-Ares, Spain
- 14:57 PL02A.04: Discussant**
Charles Rudin, USA
- 15:04 PL02A.05: IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab**
Nasser Altorki, USA
- 15:14 PL02A.06: Discussant**
Ichiro Yoshino, Japan
- 15:21 PL02A.07: Global Variability in Lung Cancer Deaths Attributable to Air Pollution**
Christine Berg, USA
- 15:31 PL02A.08: Discussant**
Joachim Aerts, Netherlands
- 15:38 PL02A.09: International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials**
Matthew Smeltzer, USA
- 15:48 PL02A.10: Discussant**
Marina Chiara Garassino, USA
- 15:55 PL02A.11: Live Discussion with Speakers**

Day 3 | Friday, September 10, 2021

05:45 - 06:45 **IS08: Industry Symposium Sponsored by Eli Lilly And Company: Personalizing and Optimizing Treatment for Metastatic NSCLC Patients with EGFR Mutations - Is There More We Can Do?**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 05:45 **IS08.01: Welcome and Introduction**
Joshua Sabari, USA.
- 05:50 **IS08.02: Is a One Size Fits All Approach Still Appropriate for NSCLC with an EGFR Mutation, Are All Mutations Equal?**
Silvia Novello, Italy
- 06:05 **IS08.03: Scientific Rationale for Dual Inhibition of VEGF and EGFR**
Nobuyuki Takakura, Japan
- 06:15 **IS08.04: Identifying the Clinical and Disease Characteristics of the High Risk Patient, What Is the Science Telling Us?**
Myung-Ju Ahn, Korea
- 06:25 **IS08.05: Panel Discussion and Q&A**
- 06:40 **IS08.06: Symposium Closing Remarks**
Mark Socinski, USA

05:45 - 06:45 **IS09: Industry Symposium Sponsored by Janssen Pharmaceutical Research & Development: Innovations in Lung Cancer Detection and Management of Non-Small Cell Lung Cancer (NSCLC) With Targeted Therapy**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 05:45 **IS09.01: Welcome and Introductions**
Lecia V. Sequist, USA
- 05:50 **IS09.02: EGFR Mutated NSCLC – Progress, Recent Developments, and Unmet Needs**
Ticiana Leal, USA & Lecia V. Sequist, USA
- 06:05 **IS09.03: Advances in Early Diagnosis, Detection and Intervention of Lung Cancer**
Chris Manley, USA
- 06:20 **IS09.04: Discussion & Q&A**

05:45 - 06:45 IS10: Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer and Validated Targets Beyond EGFR

 CME ACCREDITED BY OTHER PROVIDER

ROOM: PROGRAM AUDITORIUM

Chair: Neil Love, USA

Speakers: Ross Camidge, USA & Justin Gainor, USA & Alexander Drilon, USA

- 05:45 IS10.01: MODULE 1: Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement
- 06:00 IS10.02: MODULE 2: Current and Future Directions in the Management of ROS1-Positive NSCLC
- 06:15 IS10.03: MODULE 3: Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC
- 06:30 IS10.04: MODULE 4: Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC

07:00 - 08:00 JIES01: Joint IASLC – ESTRO Session: Advances in Radiotherapy for Lung Cancer

 NOT FOR CME CREDIT

ROOM: PROGRAM AUDITORIUM

Chairs: Umberto Ricardi, Italy & Giorgio Scagliotti, Italy

- 07:00 **JIES01.01: RT in Oligometastatic Disease**
Fiona Mary McDonald, UK
- 07:10 **JIES01.02: Radiomics and Radiotherapy: State of the Art and Future Challenges**
Dirk De Ruysscher, Netherlands
- 07:20 **JIES01.03: Combining Radiotherapy and Immunotherapy**
Corinne Faivre-Finn, UK
- 07:30 **JIES01.04: Prophylactic Cranial Irradiation in Lung Cancer: Where We Are**
Ben Slotman, Netherlands
- 07:40 **JIES01.05: Live Discussion with Speakers**

07:30 - 08:05 ES01: Proactive Tobacco and Cancer Control **IASLC CME ACCREDITED** **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Risk Reduction and Tobacco Control****Chairs: Douglas Arenberg, USA & Michael Cummings, USA**

- 07:30 ES01.01: The Influence of Lung Cancer Provider in Tobacco Control and Policy Advocacy (Summary)**
Charis Girvalaki, Greece
- 07:32 ES01.02: Setting Clinical Tobacco Cessation Efforts Up for Success (Summary)**
Joelle Fathi, USA
- 07:34 ES01.03: Integration of Cessation Services in Low Dose CT Screening (Summary)**
Emily Stone, Australia
- 07:36 ES01.04: Examining Health Outcomes in Patients Being Treated for Lung Cancer Who Smoke (Summary)**
Matt Evison, UK
- 07:38 ES01.05: Live Discussion with Speakers**

08:15 - 08:50 ES02: Multidisciplinary Collaboration in the Treatment of Oligometastatic Disease **IASLC CME ACCREDITED** **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Multimodality of Advanced Lung Cancer**
Chairs: Fiona McDonald, UK

- 08:15 ES02.01: Overview of Oligometastatic Disease (Summary)**
Ross Soo, Singapore
- 08:17 ES02.02: Surgical Trials in Oligometastatic Disease (Summary)**
Nasser Altorki, USA
- 08:19 ES02.03: Radiation Trials in Oligometastatic Disease: Any Actionable Answers? (Summary)**
Puneeth Iyengar, USA
- 08:21 ES02.04: Systemic Therapy Influenced Trials in Oligometastatic Disease (Summary)**
Paul Mitchell, Australia
- 08:23 ES02.05: Uncertainties and Controversies in Oligometastatic Disease (Summary)**
Suresh Senan, Netherlands
- 08:25 ES02.06: Live Discussion with Speakers**

08:15 - 08:50 ES03: Optimizing Survival with Multidisciplinary Collaboration **IASLC CME ACCREDITED** **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Nursing and Allied Health Professionals****Chairs: Morten Quist, Denmark & Lisa Burgess, USA**

- 08:15 ES03.01: The Effects of Lung Cancer on Patient's Sexual Functioning: Nursing View (Summary)**
Somaya Abou-Abdou, Egypt
- 08:17 ES03.02: Speech Pathology Management in Lung Cancer (Summary)**
Jacqui Frowen, Australia
- 08:19 ES03.03: Empowering Patients to Make Change: The Use of Motivational Interviewing (Summary)**
Ashlee Mulimba, UK
- 08:21 ES03.04: Multimodal Intervention (Nutrition, Exercise, Pharmacological) for Cancer Cachexia in Lung Cancer (Summary)**
Nicole Kiss, Australia
- 08:23 ES03.05: Enhanced Recovery After Thoracic Surgery (Summary)**
TaCharra Woodard, USA
- 08:25 ES03.06: Live Discussion with Speakers**

09:00 - 09:35 ES04: Antibody–Drug Conjugates: Current Status and Future Perspectives**ROOM: PROGRAM AUDITORIUM****Track: Novel Therapeutics and Targeted Therapies****Chairs: Maria Rosario García Campelo, Spain & Ana Gelatti, Brazil**

- 09:00 ES04.01: Structure and Mechanism of Antibody Drug Conjugates (Summary)**
Bob Li, USA
- 09:02 ES04.02: Antibody Drug Conjugates about Non-small Cell Lung Cancer (Summary)**
Hidetoshi Hayashi, Japan
- 09:04 ES04.03: Antibody Drug Conjugates for Other Thoracic Tumor Types (Summary)**
David Planchard, France
- 09:06 ES04.04: Antibody Drug Conjugates for Combination Therapy (Summary)**
Byoung Chul Cho, Korea
- 09:08 ES04.05: Live Discussion with Speakers**

09:00 - 09:35 ES05: A New Era of Treatment and Diagnosis for Mesothelioma and Thymoma**ROOM: PROGRAM AUDITORIUM****Track: Mesothelioma, Thymoma and Other Thoracic Malignancies****Chairs: Hedy Lee Kindler, USA & Anne Tsao, USA**

- 09:00 ES05.01: Molecular Markers in Mesothelioma (Summary)**
Jennifer Sauter, USA
- 09:02 ES05.02: Advances in Immunotherapy in Mesothelioma (Summary)**
Arnaud Scherpereel, France
- 09:04 ES05.03: CAR T-cell Therapy in Mesothelioma and Thymic Cancer (Summary)**
Joachim Aerts, Netherlands
- 09:06 ES05.04: The Latest Updates in Thymoma (Summary)**
Meinoshin Okumura, Japan
- 09:08 ES05.05: Live Discussion with Speakers**

09:45 - 10:20 ES06: Immuno-Biology and Novel Immunotherapeutics in Lung Cancer**ROOM: PROGRAM AUDITORIUM****Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)****Chairs: Jordi Remon, Spain & Lizza Hendriks, Netherlands**

- 09:45 ES06.01: Task Force in Methodology: Developing New Trials with Immunotherapeutic Agents (Summary)**
Rosalyn Juergens, Canada
- 09:47 ES06.02: Bi-Specific Agents (Summary)**
Taofeek Owonikoko, USA
- 09:49 ES06.03: "Not Just Another irAE" - Identification and Management of Immunotoxicities of Bispecifics and CAR-T (Summary)**
Melissa Johnson, USA
- 09:51 ES06.04: Intra-tumoral Immunotherapy (Summary)**
Stephane Champiat, France
- 09:53 ES06.05: Approach to Chemotherapy for Oncogene-driven Cancers: Known Barriers and Future Promise (Summary)**
Noemi Reguart, Spain
- 09:55 ES06.06: Live Discussion with Speakers**

09:45 - 10:20 ES07: Grief and Loss in Palliative Care**ROOM: PROGRAM AUDITORIUM****Track: Palliative and Supportive Care****Chair: Andreas Charalambous, Cyprus**

- 09:45 ES07.01: Grief and Loss for the Patient (Summary)**
Celia Marston, Australia
- 09:47 ES07.02: Non-pharmacologic Interventions for Physical Symptoms (Summary)**
Alex Molasiotis, HongKong
- 09:49 ES07.03: Psychosocial Interventions for Patients (Summary)**
Gary Rodin, Canada
- 09:51 ES07.04: Communication in Palliative Care Settings (Summary)**
Rachelle Bernacki, USA
- 09:53 ES07.05: Grief and Loss for Clinicians and Clinician Self-care (Summary)**
Sonia Oyola, USA
- 09:55 ES07.06: Live Discussion with Speakers**

10:30 - 11:05 ES08: What has COVID-19 Taught Us About Improving Management of Treatment for Patients with Lung Cancer **IASLC CME ACCREDITED** **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Management of Lung Cancer in the Era of COVID-19**
Chairs: Amy Moore, USA & Fred R. Hirsch, USA

- 10:30 ES08.01: COVID-19 Vaccines (Summary)**
Anne-Marie Dingemans, Netherlands
- 10:32 ES08.02: What has COVID-19 Taught Us About Improving Management of Treatment for Patients with Lung Cancer? (Summary)**
Gilberto Lopes, USA
- 10:34 ES08.03: Long-Term Outcomes (Summary)**
Annalisa Trama, Italy
- 10:36 ES08.04: COVID-19 in Lower and Middle-Income Countries (Summary)**
Luis Corrales, Costa Rica
- 10:38 ES08.05: Live Discussion with Speakers**

10:30 - 11:05 **ES09: Pathology Assessment and Biomarker Testing: Implications of and for Adjuvant and Neoadjuvant Therapy**

 **IASLC CME ACCREDITED**

 **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)**

ROOM: PROGRAM AUDITORIUM

Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
Chairs: Dara Aisner, USA & Wendy Cooper, Australia

- 10:30 **ES09.01: Adjuvant and Neoadjuvant Therapy for NSCLC – Current and Future Perspectives (Summary)**
Daniel Tan, Singapore
- 10:32 **ES09.02: Pathological Assessment Following Neoadjuvant Therapy: Challenges and Pitfalls (Summary)**
Sanja Dacic, USA
- 10:34 **ES09.03: The Role of Biomarkers for Immunotherapy in the Adjuvant and Neoadjuvant Setting (Summary)**
Francois Ghiringhelli, France
- 10:36 **ES09.04: The Role of Biomarkers for Targeted Therapy in the Adjuvant and Neoadjuvant Setting (Summary)**
Fernando Lopez-Rios, Spain
- 10:38 **ES09.05: Facilitating Biomarker Discovery in the Adjuvant and Neoadjuvant Setting (Summary)**
Janis Taube, USA
- 10:40 **ES09.06: Tobacco Moment: The Criticality of Development of a Validated Tobacco Use Measurement Tool in Clinical Trials (Captured, Considered in Clinical Endpoints and Final Analysis)**
Carolyn Dresler, USA
- 10:43 **ES09.07: Live Discussion with Speakers**

11:15 - 11:50

ES10: Optimizing Clinical Outcomes in Lung Cancer: The Value of Tobacco Cessation

IASLC CME ACCREDITED



PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)

ROOM: PROGRAM AUDITORIUM**Track: Risk Reduction and Tobacco Control****Chairs: Meredith Giuliani, Canada & Antonella Cardone, Belgium**

- 11:15 **ES10.01: Biologic and Translational Considerations of Tobacco Use Related to Therapeutic Outcomes (Summary)**
Graham Warren, USA
- 11:17 **ES10.03: Impact of Smoking on Clinical Outcomes of Radiotherapy (Summary)**
Jacek Jassem, Poland
- 11:19 **ES10.04: Smoking and Cancer Clinical Trials (Summary)**
William Evans, Canada
- 11:21 **ES10.05: Tobacco Dependence Treatment Guideline Update (American Thoracic Society Tobacco Treatment Guidelines released in 2020)**
Frank Leone, USA
- 11:23 **ES10.06: Live Discussion with Speakers**

11:15 - 11:50 **ES11: Small Cell Lung Cancer: Recent Preclinical Advances and Emerging Approaches to Therapy**

 **IASLC CME ACCREDITED**

 **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)**

ROOM: PROGRAM AUDITORIUM

Track: Small Cell Lung Cancer/ NET
Chairs: Ticiana Leal, USA & J.T. Poirier, USA

- 11:15 **ES11.01: SCLC Subgroups and Their Potential Clinical Significance (Summary)**
Carl Gay, USA
- 11:17 **ES11.02: Advances in Thoracic Radiation in SCLC (Summary)**
Bjørn Grønberg, Norway
- 11:19 **ES11.03: Emerging Strategies in ES-SCLC in the Frontline (Summary)**
Qing Zhou, China
- 11:21 **ES11.04: Treatment Options for Second-line and Beyond in ES-SCLC (Summary)**
Victoria Lai, USA
- 11:23 **ES11.05: Mechanisms of Resistance in SCLC (Summary)**
Lauren Byers, USA
- 11:25 **ES11.06: Live Discussion with Speakers**

12:00 - 13:00 **BEDG01: Brain Exchange Session – Meet the Nurse and Allied Health Committee**

 **NOT FOR CME CREDIT**

ROOM: BRAIN EXCHANGE LOUNGE

Meeting will be hosted in Zoom. Limited Capacity

BEDG01.01: Join the IASLC Nurse and Allied Health Committee for an Interactive Discussion about How to Build Your Career, Finding and Being a Good Mentor, Best Practices for the Field, Why Being Involved in IASLC Helped Their Careers, and So Much More

Morten Quist, Denmark & Melissa Culligan, USA & Csaba Degi, Romania & Michelle Turner, USA

12:00 - 13:00 **BEDG02: Brain Exchange Session – Lung Ambition Alliance with AstraZeneca - Accelerating the Early Diagnosis of Lung Cancer at Local Level**

 **NOT FOR CME CREDIT**

ROOM: BRAIN EXCHANGE LOUNGE

Meeting will be hosted in Zoom. Limited Capacity

12:00 - 13:00 BEDG03: Brain Exchange Session – Sip and Chat with the FDA**✗ NOT FOR CME CREDIT****ROOM: BRAIN EXCHANGE LOUNGE***Meeting will be hosted in Zoom. Limited Capacity***BEDG03.01: Early Stage Trials and Recent Approvals***Erin Larkins, USA & Nicole Drezner, USA & Paz Vellanki, USA***BEDG03.02: Endpoints & Path CR***Erin Larkins, USA & Nicole Drezner, USA & Paz Vellanki, USA***BEDG03.03: Precision Medicine***Erin Larkins, USA & Nicole Drezner, USA & Paz Vellanki, USA***12:00 - 13:00 BEDG04: Brain Exchange Session by AstraZeneca: 'Defining Cure' in Stage III Unresectable NSCLC. Management to Long Term Survivors****✗ NOT FOR CME CREDIT****ROOM: BRAIN EXCHANGE LOUNGE****Chair: Suresh Ramalingam, USA***Meeting will be hosted in Zoom. Limited Capacity*

- Defining "Cure" in Long Term Survivors in Early Stage Lung Cancer. Current Definition of Cure in NSCLC Clinical Practice.
- Identification and Management/Surveillance of Patients With Early Stage Who Achieve Long-Term Survival.

12:00 - 13:00 BEDG05: Brain Exchange Session by Oncocyte: Management of Early-Stage NSCLC**✗ NOT FOR CME CREDIT****ROOM: BRAIN EXCHANGE LOUNGE****Chairs: Sara Riordan, USA***Meeting will be hosted in Zoom. Limited Capacity*

- Frequency of Oncologists Managing Early-stage NSCLC
- Current Molecular Landscape for Patients with Early-stage NSCLC
- The Multidisciplinary Approach to Managing NSCLC
- Assessment of Current and Prospective Treatments for Early-stage NSCLC - How Do These Advancements in Therapy Change How the Patient Is Treated?

Day 4 | Saturday, September 11, 2021

08:00 - 09:30 **WS01: Middle East/North Africa Workshop: Presenting the Current Status and Future of Lung Cancer Detection and Treatment in the Region**

 NOT FOR CME CREDIT

ROOM: PROGRAM AUDITORIUM

Chairs: Abdul-Rhaman Jazieh, Saudi Arabia & Khaled AlKattan, Saudi Arabia

- 08:00 WS01.01: Chairs Welcome**
Abdul-Rhaman Jazieh, Saudi Arabia & Khaled AlKattan, Saudi Arabia
- 08:02 WS01.03: Tobacco Control and Smoking Cessation**
Maya Alroumani, Lebanon
- 08:17 WS01.04: Lung Cancer Screening**
Mashael Alrujaib, Saudi Arabia
- 08:32 WS01.05: Egypt Tobacco Control and Lung Cancer Screening Efforts**
Ola Khorshid, Egypt
- 08:47 WS01.06: Live Q&A/Panel Discussion with Country Reports from Morocco, Algeria, Qatar and Egypt**
Hassan Errihani, Morocco & Adda Boundejar, Algeria & Ussama Alhomsy, Qatar & Ola Khorshid, Egypt & Abdul-Rahman Jazieh, Saudi Arabia & Khaled AlKattan, Saudi Arabia

11:30 - 13:00**WS02: Early Career Workshop** **NOT FOR CME CREDIT****ROOM: PROGRAM AUDITORIUM****Chairs: Thomas Stinchcombe, USA & Kristin Higgins, USA & David Harpole, USA**

- 11:30 WS02.01: Introduction**
Thomas Stinchcombe, USA & Kristin Higgins, USA & David Harpole, USA
- 11:35 WS02.02: How to Maximize Success in Publications for JTO - Writing a Compelling Manuscript**
Emily Stone, Australia & Cheryl Ho, Canada
- 11:45 WS02.03: How to Create Your First Clinical Trial**
Kristin Higgins, USA & Salma Jabbour, USA
- 11:55 WS02.04: How to Create Programmatic Growth in the Community Setting**
Luis Raez, USA
- 12:05 WS02.05: How to Move to Different Positions/Areas of Practice Research? How to Pivot Within Your Career?**
Mark Socinski, USA
- 12:15 WS02.06: How to Get Promoted**
Taofeek Owonikoko, USA
- 12:25 WS02.07: How to Establish International Collaborations/Navigating Large International Trials**
Tom Treasure, UK
- 12:35 WS02.08: Breakout Rooms for Each Topic**
Emily Stone, Australia & Cheryl Ho, Canada & Kristin Higgins, USA & Salma Jabbour, USA & Luis Raez, USA & Mark Socinski, USA & Vassiliki Papadimitrakopoulou, USA & Taofeek Owonikoko, USA & David Harpole, USA & Tom Treasure, UK & Marina Garassino, Italy & Marie Suga, USA

13:45 - 15:15**WS03: Women in Thoracic Oncology Workshop****ROOM: PROGRAM AUDITORIUM**

Chairs: Heather Wakelee, USA & Clarissa Mathias, Brazil & Narjust Duma, USA & Deborah Doroshow, USA

13:45 WS03.01: Introduction

Heather Wakelee, USA & Clarissa Mathias, Brazil & Narjust Duma, USA & Deborah Doroshow, USA

13:50 WS03.02: Keynote

Lori Pierce, USA

14:10 WS03.03: Breakout Room Moderator

Triparna Sen, USA & Julie Brahmer, USA & Alice Berger, USA & Paula Ugalde, Canada & Rabab Gaafar, Egypt & Sabita Jiwnani, India & Pilar Garrido, Spain & Kate Sutherland, Australia

14:50 WS03.04: Panel Discussion

16:00 - 17:30 **WS04: LATAM Regional Workshop: Working to Improve Lung Cancer Disparities in LATAM**

 NOT FOR CME CREDIT

ROOM: PROGRAM AUDITORIUM

Chairs: Clarissa Mathias, Brazil & Luis Raez, USA

- | | |
|-------|---|
| 16:00 | WS04.01: Introduction
<i>Clarissa Mathias, Brazil & Luis Raez, USA</i> |
| 16:02 | WS04.02: Access to Biomarker Testing in Latin America
<i>Rodrigo Dienstmann, Brazil</i> |
| 16:12 | WS04.03: Establishing Lung Cancer Screening Programs
<i>Lucia Viola, Colombia</i> |
| 16:22 | WS04.04: Challenges to Access to Targeted Therapies and Immunotherapy in Latin America
<i>Andres Cardona Zorrilla, Colombia</i> |
| 16:32 | WS04.05: Social Vulnerability Is an Independent Risk Factor in Patients Undergoing Surgical Treatment of Lung Cancer
<i>Ricardo Terra, Brazil</i> |
| 16:42 | WS04.06: Development of Machine Learning Model to Estimate Overall Survival in Patients with Advanced NSCLC and ECOG-PS > 1
<i>Mateus Cunha, Brazil</i> |
| 16:52 | WS04.07: Machine Learning for Prediction of Survival and Risk of Mortality in Patients with Lung Cancer Undergoing Resection
<i>Renata Faccioli, Brazil</i> |
| 17:02 | WS04.08: Discussant
<i>David Carbone, USA</i> |
| 17:10 | WS04.09: Live Panel Discussion with Speakers and Chairs |

20:00 - 21:30 WS05: South/South-East Asia Workshop: Lung Cancer Diagnosis and Management with Resource Constraints in South and South-East Asia**✕ NOT FOR CME CREDIT****ROOM: PROGRAM AUDITORIUM****Chairs: Chong Kin Liam, Malaysia & Navneet Singh, India**

- 20:00 WS05.01: Introduction**
Chong Kin Liam, Malaysia
- 20:02 WS05.02: Diagnostic and Molecular Testing: Prioritizing Both Tissue and Resources**
Deepali Jain, India
- 20:17 WS05.03: Treatment of Advanced and Metastatic NSCLC without Oncogenic Drivers: Balancing Cost and Efficacy**
Thanyanan Reungwetwattana, Thailand
- 20:32 WS05.04: Treatment of Oncogene Driven Advanced and Metastatic NSCLC: Balancing Cost and Efficacy**
Navneet Singh, India
- 20:47 WS05.05: Discussant**
Chong Kin Liam, Malaysia
- 21:02 WS05.06: Live Panel Discussion**
Adnan Jabbar, Pakistan & Deebya Raj Mishra, Nepal & Roselle Guzman, Philippines

22:15 - 23:45 **WS06: Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer**

 NOT FOR CME CREDIT

ROOM: PROGRAM AUDITORIUM

Chairs: Caicun Zhou, China & Chun Xue Bai, China

- 22:15 WS06.01: Introduction**
Caicun Zhou, China & Chun Xue Bai, China
- 22:17 WS06.02: RWS on PNapp MIOT Study on Pulmonary Nodule and Updates of 9th Edition of NSCLC TNM Staging Project in China**
Dawei Yang, China
- 22:29 WS06.03: Neoadjuvant/Adjuvant Target Therapy for Curing Driver Genes Positive Resectable NSCLC**
Wen-zhao Zhong, China
- 22:41 WS06.04: Neoadjuvant/Adjuvant Immunotherapy for Curing Non-driver Genes Resectable NSCLC**
Heather Wakelee, USA
- 22:53 WS06.05: RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC**
Jie Wang, China
- 23:03 WS06.06: Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC**
Song Dong, China
- 23:13 WS06.07: Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China**
Shun Lu, China
- 23:23 WS06.08: Discussant**
Mingfang Zhao, China
- 23:31 WS06.09: Live Panel Discussion with Speakers and Chairs**
Yi-Long Wu, China & Tony Mok, HongKong

Day 5 | Sunday, September 12, 2021

15:00 - 16:00 IASLC General Assembly

 NOT FOR CME CREDIT

ROOM: PROGRAM AUDITORIUM

Welcome & Call to Order

Tetsuya Mitsudomi, Japan

Recognition of Outgoing & Incoming IASLC Board of Directors

Tetsuya Mitsudomi, Japan & Heather Wakelee, USA

Scientific Activities Report

Giorgio Scagliotti, Italy

Financial Report

John Skadow, USA

IASLC State of the State

Kristin Richeimer, USA, Interim CEO

IASLC President Parting Comments

Tetsuya Mitsudomi, Japan

Wrap Up & Adjourn

Heather Wakelee, USA

15:00 - 16:00 MTE05: Meet the Expert - Pharmaceutical/Biotech Industry

 NOT FOR CME CREDIT

ROOM: IASLC BOOTH VIA INDUSTRY HUB AND EXHIBIT HALL

Chairs: Melina Marmarelis, USA

Meeting will be hosted in Zoom. Limited Capacity

15:00 MTE05.01: Pharmaceutical/Biotech Industry

Bob Marchesani, USA

15:00 - 16:00 **MTE06: Meet the Expert - Academic and Community Crossover - Increasing Interdisciplinary Collaboration**

 NOT FOR CME CREDIT

ROOM: IASLC BOOTH VIA INDUSTRY HUB AND EXHIBIT HALL

Chairs: Sonam Puri, USA

Meeting will be hosted in Zoom. Limited Capacity

- 15:00 MTE06.01: Academic and Community Crossover - Increasing Interdisciplinary Collaboration**
Sarah Goldberg, USA

16:15 - 17:15 **PL03: Plenary 3: Screening: The Global Landscape, Progress, and Future Directions**

(Japanese, Mandarin, Spanish Translation Available)

 IASLC CME ACCREDITED

ROOM: PROGRAM AUDITORIUM

Chairs: Karen Canfell, Australia & Ella Kazerooni, USA

- 16:15 PL03.01: Lung Cancer Screening in Europe: Current Status**
Ugo Pastorino, Italy
- 16:27 PL03.02: Lung Cancer Screening in Latin America: Current Status and Challenges**
Ricardo Santos, Brazil
- 16:39 PL03.03: Lung Cancer Screening in Asia**
Li Fan, China
- 16:51 PL03.04: Radiomics in Lung Cancer Radiation Treatment Assessment: Recent Progress and Future Directions**
Fang-Fang Yin, USA
- 17:03 PL03.05: Live Discussion with Speakers**

17:30 - 18:30**MA09: Predictive Markers for Immunotherapy****ROOM: PROGRAM AUDITORIUM****Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology**

- 17:30 MA09.01: LCMC3: Immune Cell Subtypes Predict Nodal Status and Pathologic Response After Neoadjuvant Atezolizumab in Resectable NSCLC**
Filiz Oezkan, USA
- 17:35 MA09.02: SAKK 16/14 - T-Cell Receptor Repertoire Metrics Predict Response to Neoadjuvant Durvalumab in Patients With Stage IIIA(N2) NSCLC**
Sacha Rothschild, Switzerland
- 17:40 MA09.03: Peripheral CD8+ T Cells Predicts Immune-Related Adverse Events and Survival in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy**
Kan Wu, China
- 17:45 MA09.04: Discussant**
Benjamin Levy, USA
- 18:00 MA09.05: PD1-Positive Tertiary Lymphoid Structure as a Predictive Factor of Durable Clinical Effect in Immunotherapy for NSCLC**
Yuki Matsumura, Japan
- 18:05 MA09.06: Mature Tertiary Lymphoid Structures in Lung Adenocarcinoma Are Associated With Better Progression Free Survival**
Rebecca Obeng, USA
- 18:10 MA09.07: Genomic Landscape and Clinical Outcomes With Immune Checkpoint Inhibitors in NF1-Mutant NSCLC**
Marcelo Negrao, USA
- 18:15 MA09.08: Discussant**
Sabina Berezowska, Switzerland

17:30 - 18:30**MA10: Screening and Early Detection: An Overview****ROOM: PROGRAM AUDITORIUM****Track: Screening and Early Detection**

- 17:30 MA10.01: Prospective Evaluation of the International Lung Screening Trial (ILST) Protocol for Management of First Screening LDCT**
Renelle Myers, Canada
- 17:35 MA10.02: Lung Cancer Detected By Screening, Incidental Lung Nodule Program and Neither: A Prospective Observational Study**
Raymond Osarogiagbon, USA
- 17:40 MA10.03: Balance Between Decreased False Positives and Delayed Diagnosis in Lung Cancer Screening**
Rowena Yip, USA
- 17:45 MA10.04: Discussant**
Mary Pasquinelli, USA
- 18:00 MA10.05: Potential of CT and PET-Based Radiomics for the Diagnosis of Lung Adenocarcinomas Indicated for Limited Resection**
Nobuyuki Yoshiyasu, Japan
- 18:05 MA10.06: Factors Associated with Lung Cancer Screening Adherence Among Patients with Negative Baseline Nodule Finding**
Mehrad Bastani, USA
- 18:10 MA10.08: Discussant**
Nir Peled, Israel

17:30 - 18:30 OA13: Topics of Pleural Mesothelioma**ROOM: PROGRAM AUDITORIUM****Track: Mesothelioma, Thymoma and Other Thoracic Malignancies****Chair: Raphael Bueno, USA**

- 17:30 OA13.01: S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma**
Anne Tsao, USA
- 17:40 OA13.02: Socioeconomic Disparities in Access to Treatment and Survival in Operable Malignant Pleural Mesothelioma in the United States**
Estelamari Rodriguez, USA
- 17:50 OA13.03: Type M1 and Type M2 Macrophages Are Associated With Patient Survival in Malignant Pleural Mesothelioma**
Hely Ollila, Finland
- 18:00 OA13.04: Chromosomal Rearrangements and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors**
Farhad Kosari, USA
- 18:10 OA13.05: Discussant**
Harvey Pass, USA
- 18:20 OA13.06: Live Discussion with Speakers**

18:45 - 19:45**MA11: New Biological Insights for Targeted Therapies****ROOM: PROGRAM AUDITORIUM****Track: Tumor Biology and Systems Biology: Basic and Translational Science**

- 18:45 MA11.01: Development of Novel EGFR Mutant NSCLC Mouse Models and Murine Cell Lines: New Tools for NSCLC Research**
Emily Kleczko, USA
- 18:50 MA11.02: Targeting HER2 Exon 20-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib**
Han Han, USA
- 18:55 MA11.03: Phase Separation Orchestrates EML4-ALK Signaling and Promotes Tumorigenesis**
Zhen Qin, China
- 19:00 MA11.04: Discussant**
Katerina Politi, USA
- 19:15 MA11.05: Lysyl Oxidase Inhibition Drives Adenocarcinoma to Squamous Cell Carcinoma Transition and Promotes Drug Resistance**
Yueqing Chen, China
- 19:20 MA11.06: Multi-Omic Characterization of Lung Tumors Implicates AKT and MYC Signaling in Adenocarcinoma to Squamous Cell Transdifferentiation**
Alvaro Quintanal-Villalonga, USA
- 19:25 MA11.07: Lung Squamous Cell Carcinoma Prognosis Based on Ferroptosis DNA Methylation Status**
Xuequan Wang, China
- 19:30 MA11.08: Discussant**
Humam Kadara, USA

18:45 - 19:45 OA14: Global Disparities in Lung Cancer Care IASLC CME ACCREDITED**ROOM: PROGRAM AUDITORIUM****Track: Global Health****Chair: Luis Mas, USA****18:45 OA14.01: Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)***Virginia Calvo, Spain***18:55 OA14.02: Social Vulnerability Is an Independent Risk Factor in Patients Undergoing Surgical Treatment of Lung Cancer***Ricardo Terra, Brazil***19:05 OA14.03: Discussant***Nan Wu, China***19:15 OA14.04: Live Discussion with Speakers****18:45 - 19:45 OA15: Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation** IASLC CME ACCREDITED**ROOM: PROGRAM AUDITORIUM****Track: Novel Therapeutics and Targeted Therapies****Chair: Helena Yu, USA****18:45 OA15.01: Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy***Alexander Spira, USA***18:55 OA15.02: Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations***Pasi Janne, USA***19:05 OA15.03: Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS***Alexander Spira, USA***19:15 OA15.04: Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer***D. Ross Camidge, USA***19:25 OA15.05: Discussant***Federico Cappuzzo, Italy***19:35 OA15.06: Live Discussion with Speakers**

20:00 - 21:00 **MA12: The Impact of COVID-19 on How We Treat Thoracic Cancer Now and in the Future**



ROOM: PROGRAM AUDITORIUM

Track: Management of Lung Cancer in the Era of COVID-19

- 20:00 MA12.01: A Novel Program Offering Remote, Asynchronous Subspecialist Input in Thoracic Oncology: Early Experience During a Pandemic**
Howard West, USA
- 20:05 MA12.02: Factors Associated with Severe COVID-19 Infections in Lung Cancer Patients**
Apar Kishor Ganti, USA
- 20:10 MA12.03: A Thoracic Cancers International COVID 19 Collaboration Survey on Patients' Perceptions of COVID-19 (Teravolt-Paper)**
Selina Wong, USA
- 20:15 MA12.04: Discussant**
Brendon Stiles, USA
- 20:30 MA12.05: The Impact of the COVID-19 Pandemic on Post-Operative Outcomes of Thoracic Cancer Surgery in Canada**
Caroline Huynh, Canada
- 20:35 MA12.06: Single Fraction Lung Stereotactic Body Radiotherapy Implementation in a Multi-Center Provincial Cancer Program During the COVID-19 Pandemic**
Benjamin Mou, Canada
- 20:40 MA12.07: Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center**
Maristella Bungaro, Italy
- 20:45 MA12.08: Discussant**
Sara Pilotto, Italy

20:00 - 21:00 OA16: Clinical Impact of Liquid Biopsy for Patients with NSCLC**ROOM: PROGRAM AUDITORIUM****Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities****Chair: Sarah Goldberg, USA**

- 20:00 **OA16.01: Plasma NGS At Time of Diagnostic Tissue Biopsy – Impact on Time to Treatment: Results From a Pilot Prospective Study**
Jeffrey Thompson, USA
- 20:10 **OA16.02: The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer**
Doreen Ezeife, Canada
- 20:20 **OA16.03: Matched Targeted Therapy by cfDNA of CSF Beyond Leptomeningeal Metastases Progression Upon Osimertinib in EGFR-Mutated NSCLC Patients**
Mei-Mei Zheng, China
- 20:30 **OA16.04: A Combined Model of Clinical, Imaging and DNA Methylation Biomarkers to Improve the Classification of Pulmonary Nodules**
Jianxing He, China
- 20:40 **OA16.05: Discussant**
Lecia V. Sequist, USA
- 20:50 **OA16.06: Live Discussion with Speakers**

20:00 - 21:00 OA17: Multidisciplinary Care of Thoracic Oncology Patients During COVID-19 Pandemic**ROOM: PROGRAM AUDITORIUM****Track: Nursing and Allied Health Professionals****Chair: Sara McLaughlin-Barrett, Australia**

- 20:00 OA17.01: Core Supportive Care for People Living With Lung Cancer During COVID-19: Analyses of Specialist Lung Cancer Nursing Practice**
Vanessa Brunelli, Australia
- 20:10 OA17.02: COVID-19 Pandemic and Mental Health Status of Lung Cancer Patients in Indonesia**
Hanna Afladhia, Indonesia
- 20:20 OA17.03: Clinical and Social Impact of COVID-19 Pandemic in Patients with Thoracic Malignancies**
Oscar Arrieta, Mexico
- 20:30 OA17.04: The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers**
Anne-Marie Baird, Ireland
- 20:40 OA17.05: Discussant**
Michelle Turner, USA
- 20:50 OA17.06: Live Discussion with Speakers**

21:15 - 22:15**IS11: Satellite CME Symposium by Medscape: Answers to Key Questions About Molecular Alterations Within NSCLC: How Do You Stack Up?****CME ACCREDITED BY OTHER PROVIDER****ROOM: PROGRAM AUDITORIUM**

- 21:15 **IS11.01: Introduction**
Zofia Piotrowska, USA
- 21:15 **IS11.02: Key Questions for Practice: Optimizing the Diagnosis and Management of Patients with NSCLC and Molecular Alterations**
Zofia Piotrowska, USA & Joshua, Sabari, USA & Maureen Zakowski, USA
- 21:15 **Conclusions and Q&A**
Zofia Piotrowska, USA
- 21:15 **Backstage Pass Breakout Session (Optional)**

21:15 - 22:15**IS12: Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Early-Stage Non-Small Cell Lung Cancer****CME ACCREDITED BY OTHER PROVIDER****ROOM: PROGRAM AUDITORIUM**

- 21:15 **IS12.01: Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC)**
- 21:35 **IS12.02: Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC**
- 21:55 **IS12.03: Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy**

Day 6 | Monday, September 13, 2021

16:15 - 17:15**IS14: Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies** NOT FOR CME CREDIT**ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB**

- | | |
|-------|---|
| 16:15 | IS14.01: Disease Landscape Overview
<i>Luis Paz-Ares, Spain</i> |
| 16:30 | IS14.02: Pathobiology and Molecular Profile of ADC Targets in NSCLC
<i>Corey Langer, USA</i> |
| 16:40 | IS14.03: ADCs Targeting the HER Family and Clinical Data in NSCLC
<i>Keunchil Park, Korea</i> |
| 16:50 | IS14.04: Emerging ADC Targets and Clinical Data in NSCLC
<i>Marina Chiara Garassino, USA</i> |
| 17:00 | IS14.05: Faculty Panel: Live Q&A |

17:30 - 18:30**MA13: Building on the Past: What Will Be the Next Immunotherapy Combination?****IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Immunotherapy (Phase II/III Trials)**

- 17:30 MA13.01:** Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
Shengxiang (Harry) Ren, China
- 17:35 MA13.02:** Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non-Small Cell Lung Cancer
Sonam Puri, USA
- 17:40 MA13.03:** Combination of Bevacizumab + Atezolizumab (A) Who Progressed On A In Pretreated NSCLC Patients: An Open-Label, Two-Stage, Phase II Trial
Jiyun Lee, Korea
- 17:45 MA13.04:** Discussant
Alessandra Curioni-Fontecedro, Switzerland
- 18:00 MA13.05:** Prognostic Impact of Immune Related Adverse Events in Advanced Non-Small Cell Lung Cancer Patients with ICIs Treatment
Huijuan Wang, China
- 18:05 MA13.06:** Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy
Benedict Girling, UK
- 18:10 MA13.07:** GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC
Caicun Zhou, China
- 18:15 MA13.08:** CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
Jie Wang, China
- 18:20 MA13.09:** Discussant
Keunchil Park, Korea

17:30 - 18:30 OA18: Real World Data in a Modern World IASLC CME ACCREDITED**ROOM: PROGRAM AUDITORIUM****Track: Global Health****Chair: Massimo Di Maio, Italy**

- 17:30 OA18.01: Lung Cancer in Vietnam**
Sang Nguyen, USA
- 17:40 OA18.02: Canprim Beyond Oncology Into Primary Care Cancer Distress Follow-up Study Among Outpatients**
Aissa Suci, Romania
- 17:50 OA18.03: LUNGCOVID: SARS-CoV-2 Infection in Patients With Thoracic Tumors - Multicenter Observational Study in Portugal**
Denise Magalhães, Portugal
- 18:00 OA18.04: Discussant**
Bill Mayfield, USA
- 18:10 OA18.05: Live Discussion with Speakers**

17:30 - 18:30 OA19: Screening and Early Detection: State of the Art IASLC CME ACCREDITED**ROOM: PROGRAM AUDITORIUM****Track: Screening and Early Detection****Chair: John Field, UK**

- 17:30 OA19.01: Prospective Study of Lung Cancer Screening Criteria: USPSTF2013 vs PLCom2012 – International Lung Screening Trial (ILST) Results**
Martin Tammemagi, Canada
- 17:40 OA19.02: The UKLS Trial Outcome Results: Lung Cancer Mortality Reduction by LDCT Screening Confirmed in an International Meta-Analysis**
John Field, UK
- 17:50 OA19.03: Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-Dose CT Screening**
Yeon Wook Kim, Korea
- 18:00 OA19.04: Potential Clinical and Economic Impact of Missed Lung Nodules – A Claims Database Analysis**
Fernando Suarez Saiz, USA
- 18:10 OA19.05: Discussant**
Annette McWilliams, Australia
- 18:20 OA19.06: Live Discussion with Speakers**

18:45 - 19:45 **MA14: Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC**



ROOM: PROGRAM AUDITORIUM

Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology

- 18:45 MA14.01: Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non-Small Cell Lung Cancer**
Sai-Hong Ou, USA
- 18:50 MA14.02: RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study**
Fernando Lopez-Rios, Spain
- 18:55 MA14.03: Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib**
Ferdinandos Skoulidis, USA
- 19:00 MA14.04: Discussant**
Umberto Mallapelle, Italy
- 19:15 MA14.05: Clinicopathologic and Genomic Significances of the Amount of High-Grade Histologic Components in Lung Adenocarcinoma**
Bokyung Ahn, Korea
- 19:20 MA14.06: High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy**
Seung Hyeun Lee, Korea
- 19:25 MA14.07: EGFR-Mutant NSCLC With de novo or Acquired Squamous Histology: Molecular Features and Clinical Outcomes**
Catherine Meador, USA
- 19:30 MA14.08: Discussant**
Lukas Bubendorf, Switzerland

18:45 - 19:45**MA15: Real World Factors Affecting Lung Cancer Outcomes** **IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Health Services Research/Health Economics**

- 18:45** **MA15.01: Machine Learning for Prediction of Survival and Risk of Mortality in Patients with Lung Cancer Undergoing Resection**
Renata Faccioli, Brazil
- 18:50** **MA15.02: Association of Healthcare System Resources With Lung Cancer Screening Utilization**
Jennifer Lewis, USA
- 18:55** **MA15.03: Social Factors Influencing the Length of Stay in Hospital After Anatomical Resection**
Miriam Patella, Switzerland
- 19:00** **MA15.04: Discussant**
Dan Raz, USA
- 19:15** **MA15.05: Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients in The U.S. ALCHEMIST Study (Alliance)**
Kenneth Kehl, USA
- 19:20** **MA15.06: Real World Trends in Treatment Patterns for Patients With Advanced NSCLC: Comparing Changes Between Younger and Older Adults**
Bonnie Leung, Canada
- 19:25** **MA15.07: Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-small Cell Lung Cancer Patients ≥ 75 Years Old of Age**
Shinkichi Takamori, Japan
- 19:30** **MA15.08: Discussant**
Andrew Robinson, Canada

18:45 - 19:45 OA20: Exploring Treatment Modalities and Tools in Locally Advanced NSCLC**ROOM: PROGRAM AUDITORIUM****Track: Locally Advanced Non-Small Cell Lung Cancer****Chair: Leena Gandhi, USA**

- 18:45 OA20.01: Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study**
Mariano Provencio, Spain
- 18:53 OA20.02: Pre-Treatment Levels of ctDNA for Long-term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy**
Atocha Romero, Spain
- 19:01 OA20.03: Discussant**
Bruna Pellini, USA
- 19:09 OA20.04: Survival of Patients with Persistent N1 or N2 Disease After Induction Therapy for Stage IIIA-N2 Non-Small-Cell Lung Cancer**
Jorind Beqari, USA
- 19:17 OA20.05: Neoadjuvant Chemotherapy-alone vs Chemoradiation followed by Sleeve Resection for Locally Advanced Non-Small Cell Lung Cancer**
Mark Jaradeh, USA
- 19:25 OA20.06: Discussant**
Leah Backhus, USA
- 19:35 OA20.07: Live Discussion with Speakers**

20:00 - 21:00 MA16: SCLC: New Targets, Biomarkers, and Systemic Therapies**ROOM: PROGRAM AUDITORIUM****Track: Small Cell Lung Cancer/ NET**

- 20:00 MA16.01: Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer**
Vivek Subbiah, USA
- 20:05 MA16.02: Platinum-Doublets as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis**
Takashi Sato, Japan
- 20:10 MA16.03: CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer**
Alvaro Quintanal-Villalonga, USA
- 20:15 MA16.04: Discussant**
Anish Thomas, USA
- 20:30 MA16.06: Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN**
Marina Chiara Garassino, USA
- 20:35 MA16.07: Prognostic Value of 18F-Fluorodeoxyglucose Uptake of Bone Marrow on PET/CT in Patients with Limited Disease Small Cell Lung Cancer**
Merve Ayık Türk, Turkey
- 20:40 MA16.08: Discussant**
Benjamin Drapkin, USA

20:00 - 21:00 MA17: Diagnostics and Pulmonology **IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Track: Staging/Pulmonary Medicine**

- 20:00 MA17.01:** Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors
Yi-Luen Shen, Taiwan
- 20:05 MA17.02:** Visualization of Patterns of Lymph Node Metastases in Non-Small Cell Lung Cancer Using Network Graph Analysis
Yukihiro Yoshida, Japan
- 20:10 MA17.03:** Discussant
Felix Herth, Germany
- 20:25 MA17.04:** Leave Paraesophageal Lymph Node or Not in a Lung Cancer Surgery? A Propensity-Matched Analysis Based on Ten-Year Population.
Xiaofei Wang, China
- 20:30 MA17.05:** Intrapulmonary Lymph Node (LN) Retrieval With a Novel Gross Dissection Method: A Prospective, Population-Based Cohort Study
Meredith Ray, USA
- 20:35 MA17.06:** Nodal Upstaging Comparison of Open, Video-Assisted Thoracoscopic, and Robotic Lung Resections Form Non-Small Cell Lung Cancer
Ricardo Terra, Brazil
- 20:40 MA17.07:** Discussant
Young-Tae Kim, Korea

21:15 - 22:15 BEDG06: Brain Exchange Session – IASLC Language Guide Idea Exchange on Adoption and Best Practices **NOT FOR CME CREDIT****ROOM: BRAIN EXCHANGE LOUNGE***Meeting will be hosted in Zoom. Limited Capacity*

Join This Session to Learn about the New IASLC Language Guide

*Jill Feldman, USA & Kristin Ito, USA***21:15 - 22:15 BEDG07: Brain Exchange Session – Lung Ambition Alliance with AstraZeneca - Accelerating the Early Diagnosis of Lung Cancer at Local Level** **NOT FOR CME CREDIT****ROOM: BRAIN EXCHANGE LOUNGE***Meeting will be hosted in Zoom. Limited Capacity*

Day 7 | Tuesday, September 14, 2021

15:00 - 16:00 **IS15: Satellite CME Symposium by Clinical Care Options: Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer**



CME ACCREDITED BY OTHER PROVIDER

ROOM: PROGRAM AUDITORIUM

- 15:00 **IS15.01: Welcome and Introduction**
- 15:05 **IS15.02: Overview of Immunotherapy in Nonmetastatic NSCLC**
Jarushka Naidoo, USA
- 15:20 **IS15.03: Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC**
Julie Brahmer, USA
- 15:45 **IS15.04: Immunotherapy in Advanced or Metastatic NSCLC: Special Populations**
Jarushka Naidoo, USA
- 15:55 **IS15.05: Final Panel Discussion and Audience Q&A Session**

15:00 - 16:00 **IS16: Industry Symposium Sponsored by Exact Sciences: What Can We Learn from NSCLC? Using Comprehensive Genomic Profiling to Enhance Patient Care**



NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 15:00 **IS16.01: Welcome and Introductions**
Edgardo Santos, USA
- 15:05 **IS16.02: Growing Importance of Genomic Profiling**
Snehal Thakkar, USA
- 15:20 **IS16.03: Oncotype MAP™ Pan-Cancer Tissue Test: Rapid Comprehensive Genomic Profiling to Aid in Therapy Selection**
Lisa Macera, USA
- 15:35 **IS16.04: NSCLC Case Studies**
- 13:50 **IS16.05: Q&A**

15:00 - 16:00 IS17: Satellite CME Symposium by PeerView Institute for Medical Education: Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapy to Address Unmet Needs in Advanced NSCLC

 CME ACCREDITED BY OTHER PROVIDER

ROOM: PROGRAM AUDITORIUM

- 15:00 **IS17.01:** Welcome and Introduction
- 15:05 **IS17.02:** MasterClass: Leveraging Biomarker Testing for HER2, HER3, and TROP2 in Metastatic NSCLC to Determine the Right Treatment for the Right Patient
- 15:25 **IS17.03:** Clinical Accelerator: Translating Science, Transforming Practice
- 15:45 **IS17.04:** Synthesis and Conclusions

15:00 - 16:00 MTE07: Meet the Expert - Relationship Between IASLC and Advocates/IASLC's Efforts to Push Advocacy Forward Including Consideration of Innovation, AI, and Personalized Medicine to Benefit Patients with Cancer

 NOT FOR CME CREDIT

ROOM: IASLC BOOTH VIA INDUSTRY HUB AND EXHIBIT HALL

Chair: Bonnie Addario, USA

Meeting will be hosted in Zoom. Limited Capacity

- 15:00 **MTE07.01:** Relationship Between IASLC and Advocates/IASLC's Efforts to Push Advocacy Forward Including Consideration of Innovation, AI, and Personalized Medicine to Benefit Patients with Cancer
Chris Draft, USA

15:00 - 16:00 MTE08: Meet the Expert - SCLC

 NOT FOR CME CREDIT

ROOM: IASLC BOOTH VIA INDUSTRY HUB AND EXHIBIT HALL

Chair: Ronald Natale, USA

Meeting will be hosted in Zoom. Limited Capacity

- 15:00 **MTE08.01:** SCLC
Antoinette Wozniak, USA

16:15 - 17:15**PL04: Plenary 4: Stigma as Risk Factor: Why You Should Care***(Japanese, Mandarin, Spanish Translation Available)***IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Chair: Heather Wakelee, USA & Merel Hennink, Netherlands**

- 16:15** **PL04.01: The Collective Perspective from Patients/Families with an Untold Story and Foresight for What Is Needed**
Jill Feldman, USA
- 16:22** **PL04.02: NLCRT Campaign to End Lung Cancer Stigma**
Jamie Studts, USA
- 16:32** **PL04.03: Talk About Solutions: Empathic Communication Module, Language Guide, Projects and Deliverables in Stigma with Attention to the Intersection of Patients, Clinicians and Researchers**
Jamie Ostroff, USA & Smita Banerjee, USA
- 16:42** **PL04.04: Psychological Distress and Stigma for People with Lung Cancer: Time to Act**
Suzanne Chambers, Australia
- 16:47** **PL04.05: Stigma as Risk Factor - Why You Should Care**
Kazuo Hasegawa, Japan
- 16:52** **PL04.06: 'I Didn't Smoke' Language and Stigma Surrounding Lung Cancer (Personal Experience)**
Gina Hollenbeck, USA
- 16:55** **PL04.07: Live Discussion with Speakers**

17:30 - 18:05 ES12: A Precision Approach to Stage III Non-small Cell Lung Cancer**ROOM: PROGRAM AUDITORIUM****Track: Locally Advanced Non-Small Cell Lung Cancer****Chairs: Benjamin Besse, France & Jhanelle Gray, USA**

- 17:30 ES12.01: Defining Operability (Summary)**
Isabelle Opitz, Switzerland
- 17:32 ES12.02: Radiation Implications in Locally Advanced Lung Cancer (Summary)**
Stephen Chun, USA
- 17:34 ES12.03: Adjuvant and Neoadjuvant Approaches in Stage III Non-Small Cell Lung Cancer (Summary)**
Sonam Puri, USA
- 17:36 ES12.04: Survivorship in Stage III Non-small Cell Lung Cancer: A Precision Approach (Summary)**
Abhishek Shankar, India
- 17:38 ES12.05: Tobacco Moment: Critical Components of Successful Smoking Cessation Outcomes (Summary)**
Magdalena Cedzynska, Poland
- 17:41 ES12.06: Live Discussion with Speakers**

17:30 - 18:05 ES13: Ethics, Costs, and Regulation of Lung Cancer**ROOM: PROGRAM AUDITORIUM****Track: Health Services Research/Health Economics****Chairs: Bishal Gyawali, Canada & Loretta Erhunmwunsee, USA**

- 17:30 ES13.01: Immunotherapy Forever? Ideal Duration and Opportunities for De-escalation of Treatment in Lung Cancer Immunotherapy (Summary)**
Yasushi Goto, Japan
- 17:32 ES13.02: Barriers for Access to Curative Lung Cancer Treatment: What Can We Do About it? (Summary)**
Timothy Hanna, Canada
- 17:34 ES13.03: Financial Toxicity of Cancer Treatment: Moving the Discussion from Acknowledgement of Problems to Identifying Solutions (Summary)**
Bhawna Sirohi, India
- 17:36 ES13.04: What Evidence Level is Enough for Approval and Reimbursement of Novel Cancer Drugs? Lessons from Lung Cancer (Summary)**
Howard West, USA
- 17:38 ES13.05: The Ethics of International Research (Summary)**
Rebecca Pentz, USA
- 17:40 ES13.06: Tobacco Moment: The Intersection of Tobacco Use, Health Disparities, and Inequities in Lung Cancer, Treatment, and Survival**
Abhishek Shankar, India
- 17:43 ES13.07: Live Discussion with Speakers**

18:15 - 18:50**ES14: Liquid Biopsy and Other Non-invasive Diagnostic Modalities****IASLC CME ACCREDITED****PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities****Chair: Lynette Sholl, USA**

- 18:15** **ES14.01:** Incorporating ctDNA Testing into Management of Advanced NSCLC Patients (Summary)
Natasha Leigh, Canada
- 18:17** **ES14.02:** Technical Considerations/Pitfalls in ctDNA Testing
in Advanced NSCLC Patients (Summary)
Maria Arcila, USA
- 18:19** **ES14.03:** Liquid Biopsy and Early NSCLC Detection (Summary)
Christian Rolfo, USA
- 18:21** **ES14.04:** ctDNA for Minimal Residual Disease Detection (Summary)
Max Diehn, USA
- 18:23** **ES14.05:** Live Discussion with Speakers

18:15 - 18:50**ES15: The Impact of Implicit Biases in Oncology Care****IASLC CME ACCREDITED****PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Patient Advocacy****Chairs: Ewelina Szmytko, Poland & Ivy Elkins, USA**

- 18:15** **ES15.01: The Elephant in the Room (Summary)**
Jill Feldman, USA
- 18:17** **ES15.02: Implicit Bias Related to Social Determinants of Health (Summary)**
Lillian Leigh, Australia
- 18:19** **ES15.04: Implicit Bias in Cancer Research (Summary)**
Sigourney Bell, UK
- 18:21** **ES15.05: Global Perspectives on Implicit Bias in Oncology Care: India (Summary)**
Vivek Tomar, India
- 18:23** **ES15.06: Global Perspectives on Implicit Bias in Oncology Care: Canada (Summary)**
Christina Sit, Canada
- 18:25** **ES15.07: Live Discussion with Speakers**

19:00 - 19:35 ES16: Evolving Science for Stage I Non-small Cell Lung Cancer**ROOM: PROGRAM AUDITORIUM****Track: Early Stage/Localized Disease/Ablative Therapies****Chairs: Jessica Donington**

- 19:00 ES16.01: Pathologic Evaluation of Early Non-small Cell Lung Cancer (Summary)**
Mary Beth Beasley, USA
- 19:02 ES16.02: Surgical Strategy for Early Non-Small Cell Lung Cancer (Summary)**
Hisashi Saji, Japan
- 19:04 ES16.03: Radiation Oncology in Early Stage/ Localized Disease (Summary)**
Matthias Guckenberger, Switzerland
- 19:06 ES16.04: Insights from SABR COMET and SABR Bridge (Summary)**
Biniyam Kidane, Canada
- 19:08 ES16.05: Live Discussion with Speakers**

19:00 - 19:35 ES17: TNM Staging and Drug-Related Pneumonitis**ROOM: PROGRAM AUDITORIUM****Track: Staging/Pulmonary Medicine****Chairs: Paul Van Schil, Belgium & Paula Ugalde, Canada**

- 19:00 ES17.01: Current Anatomic Staging: Perspective of TNM Classification (Summary)**
Hisao Asamura, Japan
- 19:02 ES17.02: Future Directions in Staging (Summary)**
Valerie Rusch, USA
- 19:04 ES17.03: Imaging of Pneumonitis (Summary)**
Mizuki Nishino, USA
- 19:06 ES17.04: Clinical Features of "Anti-Cancer" Drug Related Pneumonitis (Summary)**
Terufumi Kato, Japan
- 19:08 ES17.05: Live Discussion with Speakers**

19:45 - 20:20 ES18: Tumor Biology and Systems Biology - Basic and Translational Science**ROOM: PROGRAM AUDITORIUM****Track: Tumor Biology and Systems Biology: Basic and Translational Science****Chairs: Huanhuan Chen, USA & Steven Dubinett, USA**

- 19:45 ES18.01: Machine Learning in Systems Approaches for Lung Cancer (Summary)**
Alex Bui, USA
- 19:47 ES18.02: Immune Alterations Associated with Progression of Bronchial Premalignant Lesions (Summary)**
Jennifer Beane, USA
- 19:49 ES18.03: The Lung Microbiome and Lung Cancer Progression (Summary)**
Leopoldo Segal, USA
- 19:51 ES18.04: Lung Cancer Early Detection Utilizing AI in CT Scan Image Analysis (Summary)**
Shuji Sakai, Japan
- 19:53 ES18.05: Response to Therapy Utilizing AI in CT Scan Image Analysis (Summary)**
Matthew Schabath, USA
- 19:55 ES18.06: Live Discussion with Speakers**

19:45 - 20:20 ES19: Lung Cancer on a Global Scale: Challenges and Innovations **IASLC CME ACCREDITED** **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Global Health**
Chair: Luis Raez, USA

- 19:45 ES19.01: Access to Targeted Therapy and Immunotherapy in Low/Medium Income (LMIC) Countries (Summary)**
Pedro Aguiar Jr., Brazil
- 19:47 ES19.02: Challenges of Lung Cancer Screening at a Global Scale (Summary)**
Pan Chyr Yang, Taiwan
- 19:49 ES19.03: Digital Therapeutics for Lung Cancer Patient Care and Remote Follow Up (Summary)**
Kaishen Chen, China
- 19:51 ES19.04: Access to Biomarker Testing in Developing Countries (Summary)**
Andres Cardona Zorrilla, Colombia
- 19:53 ES19.05: Global Collaboration for the Approval of New Lung Cancer Therapies Under FDA's Project Orbis (Summary)**
Nicole Drezner, USA
- 19:55 ES19.06: Live Discussion with Speakers**

20:30 - 21:05 ES20: Caveats, Challenges, and Controversies in Immunotherapy of Lung Cancer: Phase II and Phase III Trials **IASLC CME ACCREDITED** **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Immunotherapy (Phase II/III Trials)****Chairs: David R. Gandara, USA & Myung-Ju Ahn, Korea**

- 20:30 ES20.01: The Statistical Imperatives of Immunotherapy Research (Summary)**
Mary Redman, USA
- 20:32 ES20.02: Charting a New Path: Defining Better Endpoints in Immune Therapy Trials in Lung Cancer (Summary)**
Sanjay Popat, UK
- 20:34 ES20.03: Open and Unanswered Questions for Treatment and Needed Studies: What We Do and Do Not Know (Summary)**
Nick Pavlakis, Australia
- 20:36 ES20.04: Challenges to Expand Who Gets Immunotherapy (Summary)**
Lyudmila Bazhenova, USA
- 20:38 ES20.05: Live Discussion with Speakers**

20:30 - 21:05 ES21: Screening and Early Detection in Lung Cancer **IASLC CME ACCREDITED** **PRE-RELEASE CONTENT AVAILABLE AS OF SEPTEMBER 1 (FULL LENGTH PRESENTATION)****ROOM: PROGRAM AUDITORIUM****Track: Screening and Early Detection****Chair: Betty Tong, USA**

- 20:30 **ES21.01: The Landscape of Eligibility (Summary)**
David Baldwin, UK
- 20:32 **ES21.02: Barriers to Implementing Screening (Summary)**
Giulia Veronesi, Italy
- 20:34 **ES21.03: Evidence/ Basics to Implement a Screening Program (Summary)**
Matthijs Oudkerk, Netherlands
- 20:36 **ES21.04: Future Directions: Screening and AI (Summary)**
Mario Silva, Italy
- 20:38 **ES21.05: Future Directions: Biomarkers and Liquid Biopsy (Summary)**
Torsten Blum, Germany
- 20:40 **ES21.06: Live Discussion with Speakers**

21:15 - 22:15 PL05: Plenary 5: Closing Plenary: Immunotherapy and Beyond: Future Directions*(Japanese, Mandarin, Spanish Translation Available)* **IASLC CME ACCREDITED****ROOM: PROGRAM AUDITORIUM****Chairs: Silvia Novello, Italy & Thomas Stinchcombe, USA**

- 21:15 **PL05.01: CAR T-cell Therapy for Thoracic Cancers**
Prasad Adusumilli, USA
- 21:27 **PL05.02: Determinants of Immunotherapy Resistance in Lung Cancer**
Kurt Schalper, USA
- 21:39 **PL05.03: Radiation/IO Synergy/Evolving Technology**
Ken Harada, Japan
- 21:51 **PL05.04: IO in the Surgical Resectable Patient**
Jamie Chافت, USA
- 22:03 **PL05.05: Live Discussion with Speakers**
- 22:13 **PL05.06: Closing Remarks**

Featured Posters

✕ NOT FOR CME CREDIT

FP01	Early Stage/Localized Disease/Ablative Therapies
FP02	Health Services Research/Health Economics
FP03	Immuno-Biology and Novel Immunotherapeutics (Phase I and Translational)
FP04	Immunotherapy (Phase II/III Trials)
FP05	Liquid Biopsy and Other Non-invasive Diagnostic Modalities
FP06	Management of Lung Cancer in the Era of COVID 19
FP07	Mesothelioma, Thymoma and Other Thoracic Malignancies
FP08	Multimodality Management of Advanced Lung Cancer
FP09	Novel Therapeutics and Targeted Therapies
FP10	Palliative and Supportive Care
FP11	Patient Advocacy
FP12	Predictive Tumor Based Assays/Biomarkers/Pathology
FP13	Screening and Early Detection
FP14	Small Cell Lung Cancer/NET
FP15	Staging/Pulmonary Medicine
FP16	Tumor Biology and Systems Biology: Basic and Translational Science

FP01: Early Stage/Localized Disease/Ablative Therapies NOT FOR CME CREDIT**FP01.01: The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC**

John Varlotto, USA

FP01.02: A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial)

Ricardo Terra, Brazil

FP01.03: Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC

Sabine Schmid, Canada

FP01.04: Prospective Observational Study of Activities of Daily Livings in Elderly Patients After Lung Cancer Surgery (JCOG1710A)

Hidefumi Takei, Japan

FP02: Health Services Research/Health Economics

 NOT FOR CME CREDIT

FP02.01: Utilization and Refusal of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A National Cancer Database Study

Ranjan Pathak, USA

FP02.02: The Impact of Sex on Non-Small Cell Lung Cancer Survival in Canada

Chelsea Ford-Sahibzada, Canada

FP02.03: Factors Associated With Delayed Lung Cancer Diagnosis

Andrew Ciupek, USA

FP02.04: Immunotherapy in Lung Cancer: Analysis of Patients' Awareness and Perceptions

Christie Lagogianni, UK

FP03: Immuno-Biology and Novel Immunotherapeutics (Phase I and Translational) NOT FOR CME CREDIT**FP03.01: A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients with Metastatic Non-Small Cell Lung Cancer**

Jyoti Malhotra, USA

FP03.02: ECOG PS of 0-1 and Very High PD-L1 Expression $\geq 90\%$ Are Associated With Clinical Benefit From First-Line Chemo-Immunotherapy in Advanced NSCLC

Biagio Ricciuti, USA

FP03.03: Dasatinib Improves the Antitumor Activity of Anti-PD-1 in NSCLC Models by Inhibiting Treg Conversion and Proliferation

Esther Redin, Spain

FP04: Immunotherapy (Phase II/III Trials)

✖ NOT FOR CME CREDIT

FP04.01: Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907

Natasha Leighl, Canada

FP04.02: RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

Jie Wang, China

FP04.03: Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Igor Bondarenko, Ukraine

FP04.04: A Phase Ib/II Study of Imprime PGG and Pembrolizumab in Pretreated Patients With Advanced Stage Non-Small Cell Lung Cancer: BTCRC-LUN15-017

Muhammad Furqan, USA

FP05: Liquid Biopsy and Other Non-invasive Diagnostic Modalities

 NOT FOR CME CREDIT

FP05.01: Prevalence and Epidemiological Characteristics of Incidental Pulmonary Nodules in China: A Prospective Multicenter Trial of 10,560 Cases

Wenhua LIANG, China

FP05.03: Multiomic, Plasma-Only ctDNA NGS Assay Developed for Minimal Residual Disease (MRD) Detection in Early-Stage NSCLC

Jessica Kurata, USA

FP05.04: Robust Discrimination of Lung Cancer via Microbial DNA Detection and Machine Learning Classification

Eddie Adams, USA

FP05.05: A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation

Taku Nakagawa, Japan

FP06: Management of Lung Cancer in the Era of COVID 19

✕ NOT FOR CME CREDIT

FP06.01: Unexpected Aggressive Histological Component in Subsolid Lung Adenocarcinoma: Priority for Resection Without Delay

Masaya Yotsukura, Japan

FP06.02: The Impact of The COVID-19 Pandemic on New Diagnoses of Lung Cancer: A 3-Year Review of an Irish Cancer Centre

Hailey Carroll, Ireland

FP06.03: COVID-19: Does Thoracic Surgery Increase Mortality Rates during the Pandemic?

Maria Teresa Tsukazan, Brazil

FP07: Mesothelioma, Thymoma and Other Thoracic Malignancies NOT FOR CME CREDIT**FP07.01: The MDM2/p53 Axis is a Therapeutic Vulnerability in Malignant Pleural Mesothelioma**

Lynn Heasley, USA

FP07.02: Next Generation Sequencing Portrays Mutation Profilings of Malignant Pleural and Peritoneal Mesotheliomas

Jingquan Zhao, China

FP07.03: Diagnostic Potential of Novel Mesothelioma-Specific MicroRNAs

Michaela Kirschner, Switzerland

FP07.04: Effect of Tumor Treating Fields (TTFields) on DNA Damage and The FA-BRCA DNA Repair Pathway in Mesothelioma

Eyal Dor-On, Israel

FP07.05: DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Anna Nowak, Australia

FP08: Multimodality Management of Advanced Lung Cancer

✗ NOT FOR CME CREDIT

FP08.01: Lung Stereotactic Body Radiation Therapy for Treatment of Oligoprogressive and Oligorecurrent Metastatic Disease: A Multi-Center Analysis

Sibo Tian, USA

FP08.02: Artificial Neural Network-Based Tumour Recurrence Prediction in Non-Small Cell Lung Cancer Patients Following Radical Radiotherapy

Timothy Mitchell, UK

FP08.03: Outcomes With Multi-Disciplinary Management of Central Lung Tumors Treated With Percutaneous High-Dose-Rate Brachytherapy

Stephanie Yoon, USA

FP08.04: Tumour Spread Through Air Space (STAS) In Lung Metastases

Alberto Sandri, Italy

FP09: Novel Therapeutics and Targeted Therapies

✗ NOT FOR CME CREDIT

FP09.01: Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy

Pasi Janne, USA

FP09.02: Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

Maria Rosario García Campelo, Spain

FP09.03: Phase II Randomized Trial to Evaluate Prednisone Taper With or Without Nintedanib for the Treatment of Radiation Pneumonitis

Zachary Moore, USA

FP09.04: Impact of Brain Metastasis Status on Adverse Events (AEs) Requiring Dose Reduction Among Patients Receiving Lorlatinib

John Murphy, USA

FP10: Palliative and Supportive Care

 NOT FOR CME CREDIT

FP10.01: The Efficacy of Immunotherapy in non-Small Cell Lung Cancer Patients with Uncommon Mutations: a Real World Research from Single Site

Ying Cheng, China

FP11: Patient Advocacy

 NOT FOR CME CREDIT

FP11.01: Sustaining and Accelerating Research in Rare Oncogene-Driven Lung Cancers: Lessons From The 2020 ROS1der Research Roundtable

Janet Freeman-Daily, USA

FP12: Predictive Tumor Based Assays/Biomarkers/Pathology

✗ NOT FOR CME CREDIT

FP12.01: PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC

Sally Lau, Canada

FP12.02: Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers

Liran Holtzman, Israel

FP12.03: Associations of Urinary Biomarkers of Tobacco Toxicants With Lung Cancer Incidence in Smokers: The Multiethnic Cohort Study

Sungshim Park, USA

FP12.04: Obesity is Associated With Greater Overall Survival in Patients With Metastatic NSCLC Receiving First-Line Pembrolizumab

Findlay Thomson, UK

FP12.05: The Intrinsic Limitation and Clinical Impact of Mutant Allele-Specific Real-Time PCR-Based EGFR Mutation Assay in NSCLC

Chia-I Shen, Taiwan

FP12.06: Solid Subtype Predicts Early Bone Metastases in Sensitive EGFR-Mutated Lung Adenocarcinoma Patients After Surgery

Anning Xiong, China

FP12.07: Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients

Joshua Herman, Canada

FP12.08: Lung Adenocarcinomas with ROS1 Rearrangement show Diffuse Strong ROS1 Immunohistochemical Staining

Timothy Fielder, Australia

FP13: Screening and Early Detection

✗ NOT FOR CME CREDIT

FP13.01: Assessment of the Fear of COVID-19 and Its Impact on Lung Cancer Screening Participation Among the Korean General Population

Linh Duong, Korea

FP13.02: Costal Pleura-attached Noncalcified Nodules Newly Seen on Annual Low-Dose CT Screenings

Yeqing Zhu, USA

FP13.03: The Impact of the COVID-19 Pandemic on Lung Cancer Screening Programs in the United States

Jennifer King, USA

FP13.04: CHECK Lung Protocol: CT Lung Cancer Screening is Useful to Adjuvant Comorbid Diseases Diagnosis

Paulo Alfredo Schulze, Brazil

FP14: Small Cell Lung Cancer/NET NOT FOR CME CREDIT**FP14.01: A Phase 1b/2 Study of Autologous Dendritic Cell Vaccination in Combination With Atezolizumab in Patients With Small Cell Lung Cancer (SCLC)**

Maria Gonzalez-Cao, Spain

FP14.02: Small Cell Lung Carcinoma's Clinical Versatility Is a Manifestation of Its Shape-Shifting Cellular Programs

Mohamed Abazeed, USA

FP14.03: Diagnostic Accuracy in Central Pulmonary Carcinoid tumors is Dependent of Biopsy Size

Dwayne Naves, Netherlands

FP15: Staging/Pulmonary Medicine

✕ NOT FOR CME CREDIT

FP15.01: Randomized Single-Blind Comparative Study of Midazolam Plus Pethidine Combination and Midazolam During Bronchoscopy

Chihiro Mimura, Japan

FP16: Tumor Biology and Systems Biology: Basic and Translational Science

✗ NOT FOR CME CREDIT

-
- FP16.01:** Development and Characterization of Two Novel Squamous Cell Lung Cancer Mouse Cell Lines
Karmele Valencia, Spain
- FP16.02:** Genomic Characterization of Primary versus Metastatic Lung Adenocarcinoma
Yanyan Lou, USA
- FP16.03:** Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial
Myung-Ju Ahn, Korea
- FP16.04:** A Nationwide Population-Based Mapping of Mutations and Gene Fusions in Lung Cancer Among Never-Smokers
Annette Salomonsson, Sweden
- FP16.05** Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Combination Platinum Compound Therapy in NSCLC
Vamsidhar Velcheti, USA

Posters

✕ NOT FOR CME CREDIT

P01 – P06	Early Stage/Localized Disease/Ablative Therapies
P07	Global Health
P08 – P10:	Health Services Research/Health Economics
P11 – P12	Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
P13 – P19	Immunotherapy (Phase II/III Trials)
P21 – P24	Liquid Biopsy and Other Non-invasive Diagnostic Modalities
P25 – P30	Locally Advanced Non-Small Cell Lung Cancer
P31 – P34	Management of Lung Cancer in the Era of COVID-19
P35 – P39	Mesothelioma, Thymoma and Other Thoracic Malignancies
P40 – P43	Multimodality of Advanced Lung Cancer
P44	Nursing and Allied Health Professionals
P45 – P53	Novel Therapeutics and Targeted Therapies
P54	Palliative and Supportive Care
P55	Patient Advocacy
P56 – P60	Predictive Tumor Based Assays/ Biomarkers/ Pathology
P61 – P62	Screening and Early Detection
P63 – P66	Small Cell Lung Cancer/ NET
P67	Staging/Pulmonary Medicine
P68 – P71	Tumor Biology and Systems Biology: Basic and Translational Science

P01: Early Stage/Localized Disease/Ablative Therapies - Adjuvant Therapy

 NOT FOR CME CREDIT

P01.01: LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC

Jonathan Goldman, USA

P01.02: High Risk Factors and Benefit of Adjuvant Chemotherapy in Surgically Resected Stage IB Non-Small Cell Lung Cancer

Elizabeth Elimimian, USA

P02: Early Stage/Localized Disease/Ablative Therapies - Bronchoscopy

 NOT FOR CME CREDIT

- P02.01:** CT Integrated Bronchoscopy Manual Spraying Pigment Labeling to Localize of Small Pulmonary Nodules
Jitian Zhang, China
- P02.02:** Transbronchial Microwave Ablation of Lung Nodules in the Hybrid Operating Room – Mid-Term Follow Up of a Novel Technique
Joyce Chan, HongKong
- P02.03:** Robotic Bronchoscopy: Navigating the Change in Lung Nodule Management
Patrick Ross, USA
- P02.04:** Three Cases of Endoscopic Snare Resection for Tracheal and Main Bronchial Tumors
Fumihiko Hoshi, Japan
- P02.05:** Yield of Tumor Samples With A Guide-sheath in Endobronchial Ultrasound Transbronchial Biopsy For Non-small Cell Lung Cancer
Naoko Katsurada, Japan

P03: Early Stage/Localized Disease/Ablative Therapies - Neoadjuvant Therapy

 NOT FOR CME CREDIT

P03.01: Pathologic Response to Neoadjuvant PD-1 Inhibitors and Chemotherapy
in Squamous Non-Small-Cell Lung Cancer

Liang Shi, China

P03.02: Osimertinib as Neoadjuvant Therapy for Resectable EGFR Mutant Non-small
Cell Lung Cancer: A Real-World Multicenter Retrospective Study

Xue-Feng Leng, China

P04: Early Stage/Localized Disease/Ablative Therapies - Nodule Evaluation

 NOT FOR CME CREDIT

P04.01: Presence of Ground Glass Opacity Component is True Determinant of Prognosis in Clinical Stage I Non-Small Cell Lung Cancer

Akira Hamada, Japan

P04.02: Efficacy of Multidisciplinary Team-Based Evaluation of Patients With Suspicious Pulmonary Lesions

Federico Mazza, Italy

P05: Early Stage/Localized Disease/Ablative Therapies - SBRT NOT FOR CME CREDIT

-
- P05.01:** Personalized Optimization of TCP Using NTCP Based Constraints for Ultracentral Lung Tumors
Aditi Iyer, USA
- P05.02:** Does Non-Small Cell Lung Cancer Histologic Type Influence Outcomes with Single-Fraction Stereotactic Body Radiotherapy?
Gregory Videtic, USA
- P05.03:** Comparison of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Early-Stage NSCLC: A Systemic Review and Pooled Analysis
Ran Zhang, China
- P05.04:** Retrospective Study on the Correlation of Central Tumour and Central Structures and the Effect on Survival for Patients Receiving Lung SABR
Nur Adila Mokhtar, UK
- P05.05:** Impact of Lung Stereotactic Body Radiotherapy on Pulmonary Function Test – Experience from Tertiary Cancer Centre in India
Prachi Sawant, India
- P05.06:** Clinical Application of Anatomical Landmarkers Based 3D Precise Pulmonary Nodule Localization During Thoracoscopic Surgery
Dazhi Pang, China
- P05.07:** Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer Without Pretreatment Pathologic Results in a Chinese Population
Ran Zhang, China

P06: Early Stage/Localized Disease/Ablative Therapies - Surgery

 NOT FOR CME CREDIT

-
- P06.01:** Propensity-Matched Analysis Comparing Survival after Thoracoscopic Wedge Resection versus Segmentectomy for cT1N0 Lung Adenocarcinoma
Mong-Wei Lin, Taiwan
- P06.02:** Incorporating Surgical Collapse in the Pathological Assessment of Resected Adenocarcinoma in situ of the Lung. A Proof of Principle Study.
Hans Blaauwgeers, Netherlands
- P06.03:** The Role of Surgery for Stage 0 Adenocarcinoma in Situ of the Lung: A U.S. National Analysis
Jessica Copeland, USA
- P06.04:** Clinical Outcomes and Pathological Characteristics of Resected ALK+ Lung Adenocarcinoma: A Single Center Retrospective Analysis
Zihua Zou, China
- P06.05:** Risk Factors for Recurrence According to Site in Resected Stage I Non-Small Cell Lung Cancer
Satoshi Shiono, Japan
- P06.06:** Clinical Implications of Tumour Spread Through Air Spaces (STAS) In Lung Adenocarcinoma Patients Treated With Surgery
Laura Gutierrez Sainz, Spain
- P06.07:** Learning Curve in Robotic-Assisted Thoracoscopic Pulmonary Resection: Experience of a Brazilian Surgeon
Mariana Soares, Brazil
- P06.08:** Treatment Outcome of Second Primary Lung Cancer
Fumihiko Hoshi, Japan
- P06.09:** Lobectomy for Lung Cancer, What Is the Brazilian reality? Brazilian Society of Thoracic Surgeons Analysis
Maria Teresa Tsukazan, Brazil
- P06.10:** Low-Cost Video-Assisted Thoracic Surgery (VATS) Lobectomy Versus Regular VATS Lobectomy: A Propensity-Matched Study
Taiyang Liuru, China

P07: Global Health

 NOT FOR CME CREDIT

- P07.01:** Usage Patterns of TKIs in EGFR Mutant NSCLC: Let's Get REAL
Ullas Batra, India
- P07.02:** Real World data of Advanced Non-Small Cell Lung Cancer Patients EGFR Mutated from a Peruvian Cohort
Marco Galvez-Nino, Peru
- P07.03:** Lung Cancer Under 50 Years Old – What Reality Taught Us
Francisco Neri, Portugal
- P07.04:** Primary Lung Cancers in Patients With Head and Neck Cancer: Experience of a French Institution
Christelle Clément-Duchêne, France

P08: Health Services Research/Health Economics - Factors Affecting Clinical Outcomes

 NOT FOR CME CREDIT

- P08.01:** Building Personalized Follow-Up Care Through AI by Bringing the Lung Cancer Patient, Data Scientist and Oncologist Together
Maria Torrente, Spain
- P08.02:** Lorlatinib in First Line Treatment of Patients With ALK-Positive NSCLC: A Network Meta-Analysis
Sai-Hong Ou, USA
- P08.03:** Cost-Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non-Squamous NSCLC with High PD-L1 in Switzerland
Esther Pardo, Switzerland
- P08.04:** Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors
Lyudmila Bazhenova, USA
- P08.05:** Impact of Personal Characteristics on the Effectiveness of Immunotherapy Treatment in Late-Stage NSCLC: A Systematic Review
Krishna Patel, USA

P09: Health Services Research/Health Economics - Lung Cancer Policy

 NOT FOR CME CREDIT

-
- P09.01:** Waiting Time and Lung Cancer Outcomes: Association and Methodological Results From a Systematic Review of Systematic and Scoping Reviews
Jianrong Zhang, Australia
- P09.02:** A Clinical Evaluation Algorithm to Define Clinical Utility of Lung Nodule Diagnosis in a Multi-Collaborator Setting Using Real World Data
Stephen Deppen, USA
- P09.03:** Validation of a Real-World Mortality Endpoint for Advanced Non-Small Cell Lung Cancer Patients in China
Xian-ce Tang, China
- P09.04:** Evaluating Mutational Differences Between Hispanics and Asians in NSCLC
Robert Hsu, USA
- P09.05:** Variation of Treatment Recommendations for Stage III Non-Small-Cell Lung Cancer by Stage and Actionable Mutations
Dylann Fujimoto, USA
- P09.06:** Patient Behaviors and Attitudes Towards Lung Cancer Medication Adherence
Christie Lagogianni, UK
- P09.07:** Integration of Smoking Cessation Services in Mobile Mammography and Mobile COVID Screening to Reach Rural Populations
Haylie Reed, USA

P10: Health Services Research/Health Economics - What Happens In The Real-World?

 NOT FOR CME CREDIT

- P10.01:** Real World Data of Clinical Trial Eligibility and Outcome Analysis in Patients With Metastatic NSCLC
Amulya Yellala, USA
- P10.02:** Improved Survival of Elderly Patients with NSCLC Treated in the Immunotherapy Era: A Historical Cohort Study
Giacomo Pelizzari, Italy
- P10.03:** Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors
Shirish Gadgeel, USA
- P10.04:** Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis
Leia Khaddour, USA
- P10.05:** Adherence to Treatment Recommendations From Multidisciplinary Tumor Boards
Julia Roeper, Germany
- P10.06:** Affiliation to the Labour Market in Denmark for Patients Under 60 Years of Age After Diagnosis and Treatment for ALK-Positive NSCLC
Jon Andersen, Denmark
- P10.07:** Real-World US Treatment Patterns and Clinical Outcomes in Advanced NSCLC After Prior Platinum Chemotherapy and Immunotherapy
Timothy Smith, USA
- P10.08:** Comparing Lung Cancer in Never Smokers and Ever Smokers in Asian or Asian American Patients Treated at a Tertiary Urban Public Hospital in New York
Gianna Kroening, USA
- P10.09:** Efficacy and Toxicity of EGFR-TKI in Frail NSCLC with EGFR Mutation: A Retrospective Analysis in a Single Institution
Yuki Akazawa, Japan
- P10.10:** Trends in Treatment Patterns and Survival in Advanced NSCLC Patients Treated at Frankfurt University Hospital in 2012–2018
Andrea Wolf, Germany
- P10.11:** Real-World Experience With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer at Frankfurt University Hospital
Andrea Wolf, Germany
- P10.12:** A Thorough Look at the Clinical Characteristics and Disease Burden of Lung Cancer Patients in Chinese County Area
Jun Wan, China
- P10.13:** Real World Outcomes for Non Small Cell Lung Cancer Treated With Checkpoint Inhibitors in Lebanon, A Multicenter Observational Study
Fadi Nasr, Lebanon

P10.14: ctDNA and Real-World Response (rwR) in Patients With Lung Cancer From
A Prospective Real-World Clinico-Genomic (PCG) Study

Ari VanderWalde, USA

P11: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Clinical Trials in Progress

 NOT FOR CME CREDIT

- P11.01:** Phase I Trial of in Situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
Edward Garon, USA
- P11.02:** Targeting the Tumor Neovasculature in Lung Cancer: A Phase I Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
George Blumenschein, Jr, USA
- P11.03:** SHR-1316 in Combination With Fluzoparib in Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Two-Stage, Phase 1B Trial
Yun Fan, China

P12: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Clinical Efficacy of ICI, Predictive Biomarkers and RT Plus ICI

 NOT FOR CME CREDIT

- P12.01:** A Novel 89Zr-1-PD-1 Immuno-PET-CT May Improve Pseudoprogression Detection in a Lung Cancer Murine Model Receiving Immunotherapy
Ignacio Gil-Bazo, Spain
- P12.02:** Systemic Anticancer Therapy Upregulate Plasma Levels of Damage-Associated Molecular Patterns in Patients With Advanced Lung Cancer
Hiroyuki Inoue, Japan
- P12.03:** The Time of Anti-PD-1 Infusion Improves Survival Outcomes by Fasting Conditions Simulation in Non-Small Cell Lung Cancer
Anna Vilalta-Lacarra, Spain
- P12.04:** Radiation Mediates IDO1 Dynamic Changes in KRAS Mutation Lung Cancer Cell Lines
Yanli Lan, China
- P12.05:** Neutrophil Elastase as Combined Immunotherapy Target for Treating NSCLC
Hong Cheng, China
- P12.06:** Computational Omics Biology Model (CBM) Identifies PD-L1 Immunotherapy Response Criteria Based on Genomic Signature of NSCLC
Michael Castro, USA
- P12.07:** Radiation Mediated Down-Regulation of Indoleamine 2,3-dioxygenase 1 (IDO1) Expression in Lung Cancer Cells is Associated with iNOS-NO Pathway
Wenhu Pi, China

P13: Immunotherapy (Phase II/III Trials) - Clinical Efficacy of ICI, Predictive Biomarkers and RT Plus ICI

 NOT FOR CME CREDIT

P13.01: Use of Antibiotics Is Associated With an Increase in Immunotherapy Related Adverse Effects in Patients With Non-Small Cell Lung Cancer

Umair Majeed, USA

P14: Immunotherapy (Phase II/III Trials) - Clinical Trial in Progress

 NOT FOR CME CREDIT

- P14.01:** Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1 Positive Metastatic NSCLC
Matthew D. Hellmann, USA
- P14.02:** Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
Renaud Descourt, France
- P14.03:** Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy
Solange Peters, Switzerland
- P14.04:** A Phase 2 Multicenter Study of Iovance Autologous Tumor Infiltrating Lymphocytes (TIL, LN-145) Cell Therapy in Patients With Metastatic NSCLC
Erminia Massarelli, USA
- P14.05:** Phase 2, study of Iovance Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144, LN-145, LN-145-S1) In Patients With Solid Tumors
Scott Gettinger, USA
- P14.06:** Toripalimab in Combination With Bevacizumab and Platinum-Based Chemotherapy in Patients with Untreated Advanced ESC: A Phase II Study
Juan Li, China
- P14.07:** PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC
Alexander Spira, USA

P15: Immunotherapy (Phase II/III Trials) - Early Stage NSCLC

✖ NOT FOR CME CREDIT

- P15.01:** Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated With Neoadjuvant CCRT Followed by Surgery
Sehhoon Park, Korea
- P15.02:** Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer
Yongchang Zhang, China

P16: Immunotherapy (Phase II/III Trials) - First-Line, Advanced NSCLC

 NOT FOR CME CREDIT

-
- P16.01:** Clonal Landscape Predicts Outcome in Lung Squamous Cell Carcinoma Patients with a Low Tumor Mutational Burden
Stas Fridland, USA
- P16.02:** Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience
Samantha Dean, Australia
- P16.03:** SWItch Maintenance PEmbrolizumab in patients with Non Small Cell Lung Cancer (SWIPE): Final Analysis
Haris Charalambous, Cyprus
- P16.04:** A Phase II Clinical Study Evaluating Camrelizumab Combined With Apatinib and Albumin Paclitaxel for Advanced Non-Small Cell Lung Cancer
Lin Wu, China
- P16.05:** Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC
Maki Kobayashi, Japan
- P16.06:** Comparison of Clinical Outcomes of Patients With Advanced NSCLC In Clinical Trials and in the Real World Received PD-1/PD-L1 Inhibitor
Huijuan Wang, China
- P16.07:** ARC-10: Phase 3 Study of Zimberelimab ± Domvanalimab vs Standard Chemotherapy in Front-Line, PD-L1-High, Metastatic NSCLC
Yu-Chung Li, HongKong

P17: Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC

✖ NOT FOR CME CREDIT

- P17.01:** KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
Ying Cheng, China
- P17.02:** RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC
Shun Lu, China
- P17.03:** Sintilimab With Two Cycles Nab-Paclitaxel / Platinum as First Line Therapy for Advanced Squamous Non-Small-Cell Lung Cancer
Huijuan Wang, China

P18: Immunotherapy (Phase II/III Trials) - IO and Targeted Therapy

 NOT FOR CME CREDIT

P18.01: Treatment Efficacy of HER2-Mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors
Chunxia Su, China

P19: Immunotherapy (Phase II/III Trials) - Previously Treated NSCLC

 NOT FOR CME CREDIT

- P19.01:** RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
Yun Fan, China
- P19.02:** Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression-Free and Overall Survival
Zhehai Wang, China

P21: Liquid Biopsy and Other Non-invasive Diagnostic Modalities - IO

 NOT FOR CME CREDIT

P21.01: Selected ctDNA Panel Gene Sequencing for Neoantigen Discovery and Survival Prediction in Patients With Stage IV Non-Small Cell Lung Cancer

Feng Ming Kong, China

P21.02: Real-World Concordance Between Tumor Mutational Burden From Blood and Tissue in Lung Cancer and Other Cancers

Jewel Park, USA

P22: Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Monitoring/Prognosis

 NOT FOR CME CREDIT

- P22.01:** Personalized ctDNA Assay for MRD Detection and Treatment Response Monitoring in a Patient With Metastatic Lung Cancer
Georges Azzi, USA
- P22.02:** Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease
Namrata Patil, USA
- P22.03:** Role of Circulating Tumor Cell Subpopulations in Operable Non-Small Cell Lung Cancer Diagnosis and Prognosis
Emanuela Fina, Italy
- P22.04:** Prospective Validation of an Eight Gene mRNA Signature in Plasma for the Diagnosis of Early Stage Lung Cancer
Ana Giménez Capitán, Spain
- P22.05:** Dynamic Monitoring of Blood Samples by PEAC Technology for Early-Stage Lung Cancer Patients After Surgery
Yue Pu, China
- P22.06:** Prognostic Value of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Receiving Front-Line Treatment
Haohua Zhu, China

P23: Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Screening and Early Detection

 NOT FOR CME CREDIT

- P23.01:** Integration of Metabolomics and Transcriptomics to Reveal Metabolic Disorder in Early Lung Cancer for Non-invasive Diagnosis
Xinrong Jiang, China
- P23.02:** Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients
Carlos Pedraz-Valdunciel, Spain
- P23.03:** Novel Serum Extracellular Vesicles Based miR-153-3p Biomarker Combined to a Prediction Model for Determining Early-Stage Lung Cancer
Yuxia Deng, China
- P23.04:** Serum Biomarkers Enhance Prognostic Value of Computed Tomography (CT) in Patients With Non-Small Cell Lung Cancer (NSCLC)
Rebecca Gerber, Germany
- P23.05:** Chromosome 3q22.1 and 10q22.3 Amplification in Different Subtypes of Lung Adenocarcinoma
Qi Wang, China

P24: Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Targeted Therapy



- P24.01:** Turnaround Time and Variant Prevalence of a Blood-based KRAS Test in Patients With NSCLC
Edgardo Santos, USA
- P24.02:** Unique Efficacy of Ensartinib on Different ALK Fusion Subtypes Evaluated by Plasma ctDNA
Tao Wang, China
- P24.03:** Dynamic Circulating Tumor DNA Interim Results From The ALKternate Clinical Trial
Malinda Itchins, Australia
- P24.04:** Concordance of Tissue and Cell-Free DNA-Based Next-Generation Sequencing in Patients With Lung Adenocarcinoma
Misha Tran, USA
- P24.05:** Using Liquid Biopsies to Guide First-Line Therapy Decisions in Patients With Metastatic Non-Small Cell Lung Cancer
Luis Raez, USA
- P24.06:** Resistance Mechanisms Exploring of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study
Guilan Dong, China
- P24.07:** An Ultra-Sensitive Protocol for ctDNA Mutation Detection With Application in Lung Cancers
Yue Pu, China
- P24.08:** Lung Cancer Diagnosis in Absence of Adequate Tissue Molecular Analysis in Metastatic Disease by NGS Analysis of Plasma cfDNA
Christi Steendam, Netherlands
- P24.09:** Association Between Circulating EGFR Mutant Tumor DNA and Tumor Lesion Glycolysis in Patients with EGFR Mutated Metastatic Lung Adenocarcinoma
Zhasmina Mihaylova, Bulgaria
- P24.10:** Identification of ctDNA using MassARRAY Technology in a Cross-Sectional Study of NSCLC Patients
Ken O'Byrne, Australia
- P24.11:** Cell-Free Tumor DNA (ctDNA) Utility in Detection and Monitoring EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
Jason Agulnik, Canada
- P24.12:** Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Elderly Patients.
luis Basbus, Argentina
- P24.13:** Circulating Tumor Cells Predict Prognosis Following First-Generation EGFR-TKI Treatment in EGFR- and TP53-Mutant Non-Small Cell Lung Cancer
Wen Gao, China

P24.14: Validation of Companion Diagnostics for the Identification of Patients with EGFR Exon20ins NSCLC for Amivantamab Therapy

Timothy Jatkoe, USA

P25: Locally Advanced Non-Small Cell Lung Cancer - Concurrent Chemotherapy/ Radiotherapy

 NOT FOR CME CREDIT

P25.01: Efficacy of Weekly Paclitaxel-Bevacizumab Combination in Advanced NSCLC: AVATAX, A Retrospective Multicentric Study

Geoffroy Bilger, France

P25.02: Concurrent Chemoradiotherapy With Cisplatin + S-1 for Locally Advanced Non-Small Cell Lung Cancer: IPD Meta-Analysis

Yuri Taniguchi, Japan

P26: Locally Advanced Non-Small Cell Lung Cancer - EGFR Targeted Therapy

 NOT FOR CME CREDIT

P26.01: Detecting Oligo-Metastatic/Progressive Disease in Advanced EGFR-Mutant NSCLC: PET/CT and Conventional Imaging Methods

Dayu Xu, China

P26.02: A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results

Collin Blakely, USA

P27: Locally Advanced Non-Small Cell Lung Cancer - Other & Local Treatment Toxicity

 NOT FOR CME CREDIT

-
- P27.01:** Patterns of Care and Outcomes in Clinical T3N0M0 Non-Small Cell Lung Cancer Without Invasion of Other Structures
Matthew Parsons, USA
- P27.02:** Associating Cardiac Plaque Accumulation With Cardiac Toxicity and Overall Survival In Locally Advanced Non-Small Cell Lung Cancer
Andreas Rimner, USA
- P27.03:** Increase in Overall Survival for Locally Advanced NSCLC Patients From 2010 to 2018 - A Registry Based Study in Denmark
Peter Meldgaard, Denmark
- P27.04:** Clinical Outcomes for Patients With Stage III NSCLC and STK11 or KEAP1 Genetic Alterations
Sean Taasan, USA
- P27.05:** High Body Mass Index (BMI) Is Associated With Better Outcomes in Mexican Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Saul Campos-Gomez, Mexico
- P27.06:** Multiscale NSCLC Tumor Growth Knowledge-Based Model Reproduces Tumor-Non-Progression under Gefitinib
Adèle L'Hostis, France
- P27.07:** Pancoast Tumour Presenting as Lower Limb Weakness; Would You Recognise It?
Gaurav Jha, UK
- P27.08:** Accurate Positioning Technology for Lung Cancer Radiotherapy
Yaping Xu, China

P28: Locally Advanced Non-Small Cell Lung Cancer - Post PACIFIC Use of Durvalumab

 NOT FOR CME CREDIT

- P28.01:** Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC
Yiqing Huang, Singapore
- P28.02:** Beyond PACIFIC: Outcomes and Toxicity According to Durvalumab Dosing Schedule Every 2 versus 4 Weeks
Marie-Hélène Denault, Canada
- P28.03:** Durvalumab Adjuvant to Chemoradiation for Patients With Locally Advanced Non-Small Cell Lung Cancer: Real World Experience
Vilde Drageset Haakensen, Norway
- P28.04:** Pneumonitis With Durvalumab Following Concurrent Chemoradiotherapy
Wissam Hanayneh, USA

P29: Locally Advanced Non-Small Cell Lung Cancer - Radiation Planning and Delivery

 NOT FOR CME CREDIT

- P29.01:** Deformable vs. Rigid Registration in Evaluating Composite Doses to Central Organs at Risk in Thoracic Reirradiation
David Cooper, USA
- P29.02:** Early GLS Changes Detection After Chemoradiation in Locally Advanced NSCLC
Sara Ramella, Italy
- P29.03:** Thoracic Organs at Risk (OARs) Contouring Variations and Consensus in Radiation Therapy for Non-Small Cell Lung Cancer
Feng Ming Kong, China
- P29.04:** Treatment Plan Parameters and Toxicity Following Chemoradiotherapy and High-Dose Radiotherapy in Stage III Non-Small Cell Lung Cancer
Merle Ronden, Netherlands
- P29.05:** Gross Tumor Volume Contouring Variations in Radiation Therapy of Non-Small Cell Lung Cancer
Feng Ming Kong, China
- P29.06:** Both Endostar and Amifostine Reduced All the Incidence of Pneumonitis Above Grade 2 in Chemoradiotherapy With Locally Advanced NSCLC
Kuifei Chen, China
- P29.07:** A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
Juan Li, China
- P29.08:** Evaluation of the Prognostic Marker of PD-L1 Expression After Combined Radiochemotherapy in Patients With NSCLC Stage III
Jan Wagner, Germany

P30: Locally Advanced Non-Small Cell Lung Cancer - Surgery

 NOT FOR CME CREDIT

- P30.01:** Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01)
Katarzyna Furrer, Switzerland
- P30.02:** Salvage Surgery in Patients With Locally Advanced Non-Small Cell Lung Cancer – Outcomes and Longtime Results
Katarzyna Furrer, Switzerland
- P30.03:** Impact of Visceral Pleural Invasion (VPI) and lymphovascular Invasion (LVI) on Stage I Non-Small Cell Lung Cancer (NSCLC) Outcomes
Erica Cohn, USA
- P30.04:** Clinical Research on Patients With Surgically Resected Lung Adenocarcinoma Lesions: Are Heterogeneous GGNs Different From Part Solid Nodules?
Hirofumi Koike, Japan

P31: Management of Lung Cancer in the Era of COVID-19 - Impact of COVID-19 in Lung Cancer Management

 NOT FOR CME CREDIT

- P31.01:** Impact of COVID-19 on Lung Cancer Diagnosis and Treatment: A Retrospective Chart Review
Jason Agulnik, Canada
- P31.02:** Impact of COVID-19 Pandemic in Spanish and Portuguese Lung Cancer Patients
Antonio Araujo, Portugal
- P31.03:** The Impact of the COVID-19 Pandemic on a Thoracic Tumor Unit of a Tertiary Hospital in Spain
Virginia Calvo, Spain
- P31.04:** Global Impact of COVID-19 on NSCLC Surgery: Initial Analysis of the CovidSurg-Cancer Study
Akshay Patel, UK
- P31.05:** SARS-CoV-2 and Lung Cancer: Pandemic Impact in Diagnosis, Staging and Management
Maria Teresa Tsukazan, Brazil
- P31.06:** Impact of Covid-19 Infection on Lung Cancer Patients: Experience in Latin-American Country ACHOCC-19L Study
Aylen Vanessa Ospina Serrano, Colombia

P32: Management of Lung Cancer in the Era of COVID-19 - Screening and Diagnosis of Lung Cancer During COVID-19

 NOT FOR CME CREDIT

- P32.01:** Clinical Screening for COVID-19 in Asymptomatic Patients With Lung Cancer: Brazilian Experience From a Single Institution
Carlos Henrique Teixeira, Brazil
- P32.02:** 2020 in Hindsight: Newly Diagnosed Lung Cancer Patients in the Time of COVID-19 at a Tertiary Canadian Cancer Centre
Lars Petersen, Canada

P33: Management of Lung Cancer in the Era of COVID-19 - Supportive Care for Lung Cancer Patients in the Era of COVID-19

 NOT FOR CME CREDIT

P33.01: Air Leak Due COVID-19 in a Lung Cancer Patient

Avinash Aujayeb, UK

P33.02: Day Case Thoracocopy With IPC Insertion

Avinash Aujayeb, UK

P34: Management of Lung Cancer in the Era of COVID-19 - Treatment of Lung Cancer During COVID-19

 NOT FOR CME CREDIT

- P34.01:** 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era
Caera Douglas, UK
- P34.02:** The Inhibitory Effect of Cisplatin, Paclitaxel, and Pemetrexed on the Growth of PC9GR Cells During the COVID-19 Pandemic
Md Mohiuddin, Japan
- P34.03:** Lung Cancer Patients and COVID-19 in a District General Hospital in the UK
Avinash Aujayeb, UK
- P34.04:** Chemo-Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Real World Data from a Tertiary Oncology Centre
Sean Dooloo, UK
- P34.05:** Three Birds, One Stone: IVIG Use in Hypogammaglobulinemia, Checkpoint Inhibitor Pneumonitis, and Persistent COVID-19
Eric Olson, USA
- P34.06:** Antiproliferative Effects of Paclitaxel on PC9-MET Cells During the Coronavirus Disease 2019 Pandemic
Md Mohiuddin, Japan

P35: Mesothelioma, Thymoma and Other Thoracic Malignancies - Basic Research for Pleural Mesothelioma

 NOT FOR CME CREDIT

P35.01: YB-1 is a Key Player in Aggressive Behaviour and Chemoresistance in Mesothelioma

Karin Schelch, Austria

P36: Mesothelioma, Thymoma and Other Thoracic Malignancies - Case Reports in Mesothelioma and Thymoma

 NOT FOR CME CREDIT

P36.01: Primary Acinic Cell Carcinoma of Bronchial Ground Origin: A Case Report

Koichi Hirano, Japan

P36.02: A Case of Recurrent Giant Malignant Solitary Fibrous Tumour of the Pleura: An Elephant in the Room?

Sara Ricciardi, Italy

P36.03: Rapidly Progressed Anaplastic Carcinoma in the Anterior Mediastinum Successfully Treated With Gene-Targeted Therapy

Etsu Chou, Japan

P37: Mesothelioma, Thymoma and Other Thoracic Malignancies - Clinical Research for Pleural Mesothelioma

 NOT FOR CME CREDIT

- P37.01:** The Results of Multimodal Treatment With Extrapleural Pneumonectomy for Female Epithelioid Malignant Pleural Mesothelioma
Kazunori Okabe, Japan
- P37.02:** Improving Outcomes in Malignant Pleural Mesothelioma in an Integrated Health System
Stephanie Ossowski, USA
- P37.03:** The Epidemic of Malignant Mesothelioma in China: A Prediction of Incidence During 2016-2030
Zhouguang Hui, China

P38: Mesothelioma, Thymoma and Other Thoracic Malignancies - Misenous or Metastatic Lung Tumors

 NOT FOR CME CREDIT

- P38.01:** p40 and p63 Immunohistochemistry in the Diagnostic Consideration of NUT Carcinoma in the Lung
Catherine Roe, USA
- P38.02:** The Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) In Lung Metastases
Dimitrios Magouliotis, UK

P39: Mesothelioma, Thymoma and Other Thoracic Malignancies - Thymoma and Mediastinal Tumors

 NOT FOR CME CREDIT

- P39.01:** Long-Term Outcomes and Characteristics of Unresectable Locally Advanced Thymic Malignancies
Antonios Sideris, USA
- P39.02:** Does Neo-Adjuvant Chemotherapy Help in Locally Advanced Thymic Malignancy?
Srinivas Kodaganur Gopinath, India
- P39.03:** Primary Mediastinal Germ Cell Tumors: A 15-Years Experience Treatment in Rajavithi Hospital, Thailand
Kunlatida Maneenil, Thailand
- P39.04:** Thymic Epithelial Tumors: The Importance of Invasive Investigation to Adequate Diagnosis
Paulo Alfredo Schulze, Brazil
- P39.05:** Outcomes of Videothoroscopic Thymectomy for Treatment Large-Sized Thymomas
Alexandr Podobed, Belarus

P40: Multimodality of Advanced Lung Cancer - Clinical Outcomes

 NOT FOR CME CREDIT

- P40.01:** Maintenance Anlotinib After Induction Therapy With Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Phase 2 Study
Yongqian Shu, China
- P40.02:** Pemetrexed in Advanced-stage Lymphoepithelioma Carcinoma of Lung
Ri-Qiang Liao, China
- P40.03:** Palliative Radiotherapy Decreased Circulating White Blood Cells in Patients With Stage IV Lung Cancer
Feng Ming Kong, China
- P40.04:** CNS Adverse Events and Survival in Patients with NSCLC Brain Metastases Treated With Concurrent Radiation and Immunotherapy
David Riley, USA
- P40.05:** Radiation-Related Platelet Reduction in Patients With Stage IV Lung Cancer
Feng Ming Kong, China
- P40.06:** A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer
Qian Chu, China
- P40.07:** Immunotherapy Toxicity in Lung Cancer & the Impact of Thoracic Radiation Therapy
Ciani Ellison, USA
- P40.08:** Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors
Sara Manglaviti, Italy
- P40.09:** Using Real World Data to Identify a Patient Cohort Who Require Prehabilitation to Improve Treatment Rates for Stage 3 NSCLC
Benjamin W. A. Langley, UK
- P40.10:** Brain Metastases in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy. Real World Data From a Tertiary Hospital in Spain
Yago Garitaonandia, Spain
- P40.11:** Trimodality Therapy Protocol in 144 Superior Sulcus Patients: Good Results Even for Extended Resections and Indications
Marinus Paul, Netherlands
- P40.12:** Cardiotoxicity in Lung Cancer Patients Treated With Immune-Checkpoints Inhibitors
Mariola Blanco Clemente, Spain
- P40.13:** Lung Cancer 5-Year Survival in Croatia - Our Experience
Marko Jakopović, Hungary
- P40.14:** Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study
Lin Wu, China

- P40.15: Proton Pump Inhibitors, Prior Therapy and Survival in Patients Treated With Immune Checkpoint Inhibitors for Advanced NSCLC**
Mariam Husain, USA
- P40.16: Real-World Data and Racial Outcomes for NSCLC in The Chemo-Immunotherapy Era**
Danny Markabawi, USA
- P40.17: Palliative Radiotherapy Decreased K⁺ and Ca²⁺ of the Blood in Patients With Stage IV Lung Cancer**
Feng Ming Kong, China
- P40.18: Second Line Immunotherapy After Progression on a Different First Line Immunotherapy in Advanced Non-Small Cell Lung Cancer With Focus On Elderly**
Karan Seegobin, USA
- P40.19: Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer**
Sara Manglaviti, Italy
- P40.20: Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer**
Sabin Goktas Aydin, Turkey

P41: Multimodality of Advanced Lung Cancer - Clinical Trials, Case Report

✖ NOT FOR CME CREDIT

P41.01: **Abscopal Response Induced by Thermal Ablation in Advanced NSCLC Patients Failed From Immunotherapy: Preliminary Result From a Phase 2 Trial**

Chuchu Shao, China

P41.02: **Surgery for Small Pulmonary NUT Carcinoma: Case Report**

Yuichi Saito, Japan

P42: Multimodality of Advanced Lung Cancer - Prognostic Factors

 NOT FOR CME CREDIT

P42.01: Tumor Size is an Independent Prognostic Factor after Pulmonary Metastasectomy

Simona Sobrero, Italy

P42.02: Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited Country

Chawalit Chayangsu, Thailand

P42.03: Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression

Andrés Barba Joaquín, Spain

P42.04: Prognosis Factors in Advanced Lung Cancer Patients Treated With Checkpoint Inhibitor-Based Immunotherapy

Kan Wu, China

P43: Multimodality of Advanced Lung Cancer - Others

 NOT FOR CME CREDIT

- P43.01:** Three-Dimensional Virtual Planning for Nodule Resection in Solid Organs: A Systematic Review and Meta-Analysis
Paulo Alfredo Schulze, Brazil
- P43.02:** Inconsistencies Within Biomarker Test Reports Provide Opportunities for Future Patient Education
Nikki Martin, USA
- P43.03:** LUPA-01: An Observational Study to Monitor Lung Cancer Patients' Activity and Assess Performance Status through a Wearable Device in Spain
Santiago Ponce Aix, Spain

P44: Nursing and Allied Health Professionals

 NOT FOR CME CREDIT

P44.01: Clinical Predictive Markers of Response to Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC).

Raena Rhone, USA

P44.02: Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin +/- Pembrolizumab in Metastatic Non-Squamous NSCLC

Jennifer Miller, USA

P45: Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

 NOT FOR CME CREDIT

- P45.01:** Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World
Yasushi Goto, Japan
- P45.02:** Molecular Profile of Resistance Mutations Post Multiple Lines of Tyrosine Kinase Inhibitors in ALK-Positive Non-Small-Cell Lung Cancer
Moushumi Suryavanshi, India
- P45.03:** Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
Enriqueta Felip, Spain
- P45.04:** Phase II Study of Brigatinib in ROS1 Positive Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Crizotinib: Barossa Cohort 2
Jun Sakakibara-Konishi, Japan
- P45.05:** Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival
Sally Lau, Canada
- P45.06:** Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
Yi-Long Wu, China
- P45.07:** Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC
Sabine Schmid, Canada
- P45.08:** Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
Shun Lu, China
- P45.09:** Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
Simren Chotai, Canada
- P45.10:** Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis
Michela Febbraro, Canada
- P45.11:** Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer
Oscar Arrieta, Mexico
- P45.12:** Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis
Chiara Paratore, Italy
- P45.13:** Efficacy and Safety of Crizotinib in Real-World ROS1-rearranged NSCLC: A Retrospective Canadian Cohort
Amanda Gibson, Canada

- P45.14:** Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Altered Non-Small-Cell Lung Cancer Patients in China
Shaoyu Yang, China
- P45.15:** Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK+ NSCLC
Zihua Zou, China
- P45.16:** Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer
David Riley, USA
- P45.17:** Outcomes of Patients on ALK Inhibitor Therapy in NHS Tayside Scotland UK
Sherie George, UK
- P45.18:** NSCLC Patients With ALK Gene Rearrangement – Croatian Experience
Marko Jakopović, Hungary

P46: Novel Therapeutics and Targeted Therapies - Case Report

 NOT FOR CME CREDIT

- P46.01:** Progression After Targeted-therapy – An EGFR Case Report
Francisco Neri, Portugal
- P46.02:** Impact of Real-World DNA- and RNA-Based Rebiopsy Testing in EGFR-Mutated NSCLC Progressing on Osimertinib.
Edyta Urbanska, Denmark
- P46.03:** Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC
Jens Benn Sørensen, Denmark
- P46.04:** Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants
Yuta Ohishi, Japan
- P46.05:** Durable Response to Double Dose Osimertinib 160mg in EGFR-Mutated Non-Small Cell Lung Cancer With Brain Metastases
Myungwoo Nam, USA
- P46.06:** Response of an Advanced Lung Cancer Mass to Targeted Therapy
Paulo Alfredo Schulze, Brazil
- P46.07:** Afatinib-Related Pneumonitis in Metastatic EGFR-Positive NSCLC
Sita Andarini, Indonesia

P47: Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress

 NOT FOR CME CREDIT

- P47.01:** **SGNTUC-019: Phase 2 Study of Tucatinib and Trastuzumab in Solid Tumors: Lung Cancer Cohorts (Clinical Trial in Progress)**
Martin Reck, Germany
- P47.02:** **EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer**
Seema Gorla, USA
- P47.03:** **Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2**
Jonathan Goldman, USA
- P47.04:** **TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab and Platinum-Based Chemotherapy in Advanced NSCLC**
Benjamin Levy, USA
- P47.05:** **A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)**
Melissa Johnson, USA
- P47.06:** **TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC**
Hossein Borghaei, USA
- P47.07:** **KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC**
David R. Spigel, USA
- P47.08:** **A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC**
Sehhoon Park, Korea
- P47.09:** **Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2**
Christophe Doms, Belgium
- P47.10:** **Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study**
Waleed Kian, Israel
- P47.11:** **COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib**
Lecia V. Sequist, USA
- P47.12:** **ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression**
Malinda Itchins, Australia
- P47.13:** **First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors**
David R. Spigel, USA

- P47.14:** Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC
Reiko Matsuzawa, Japan
- P47.15:** A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results
Matthew Lara, USA
- P47.16:** Preliminary Efficacy and Safety Results About a Phase II Trial of Afatinib and Bevacizumab in Untreated NSCLC Harboring EGFR Sensitive Mutations
Yu Feng, China
- P47.17:** Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping-mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)
Pierre-Jean Souquet, France
- P47.18** Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial)
Nan Bi, China

Presenter: Bi Nan, China **P48: Novel Therapeutics and Targeted Therapies - EGFR**



- P48.01:** Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial
Lin Wu, China
- P48.02:** Real-World Data of Dacomitinib in EGFR TKI-Naïve Patients With Advanced Epidermal Growth Factor Receptor-positive Non-small Cell Lung Cancer
Jinyao Zhang, China
- P48.03:** Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients
Moushumi Suryavanshi, India
- P48.04:** EGFR Germline Mutations in Chinese Lung Cancer Patients: A Single Institutional, Retrospective Study
Chengzhi Zhou, China
- P48.05:** Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
Miguel Garcia, Canada
- P48.06:** A Network Meta-Analysis (MA) of First-Line Lung Cancer Treatment With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
Yvonne Ang, Singapore
- P48.07:** Real-World Impact of Upfront Osimertinib in Reducing Health Resource Utilization by Preventing Brain Metastases
Francesca Simionato, Italy
- P48.08:** The Efficacy and Clinical Survival Outcome of Different First-Line Treatments in EGFR Mutant Non-Small Cell Lung Cancer With Brain Metastases
Huijuan wang, China
- P48.09:** Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT
Oscar Arrieta, Mexico
- P48.10:** Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
Huijuan Wang, China
- P48.11:** ctDNA Dynamic Detection Reveals the Advantages of EGFR Tyrosine Kinase Inhibitors Combined With Chemotherapy in NSCLC Patients
Weineng Feng, China
- P48.12:** Concurrent Chemotherapy and First-Generation EGFR-TKI as First-Line Treatment in Advanced Lung Adenocarcinoma Harboring EGFR Mutation
Ziyi Xu, China
- P48.13:** Clinical Factors Associated With Treatment Outcomes in EGFR Mutant Non-Small Cell Lung Cancer Patients. Real Life Experience in Argentina
luis Basbus, Argentina

- P48.14:** **Metastatic NSCLC -Re-Challenging With First Generation TKI After a Drug Free Holiday After Resistance to 3rd Generation TKI**
Suryakanta Acharya, India
- P48.15:** **EGFR Mutated Non-Small Cell Lung Cancer Treatment Pathway – What Is the Best Way?**
Marta Soares, Portugal
- P48.16:** **The Effect and Safety of Anlotinib as a Third Line or Further Therapy in Non-Small Cell Lung Cancer Patients With Liver Metastasis**
Yinchen Shen, China
- P48.17:** **Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib**
Jorge Nieva, USA

P49: Novel Therapeutics and Targeted Therapies - EGFR Major

 NOT FOR CME CREDIT

P49.01: Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC

Song Dong, China

P50: Novel Therapeutics and Targeted Therapies - EGFR Minor

 NOT FOR CME CREDIT

- P50.01:** RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants
Kazumi Nishino, Japan
- P50.02:** A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
Satoru Miura, Japan
- P50.03:** Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Misako Nagasaka, USA
- P50.04:** Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study
Madhusmita Behera, USA
- P50.05:** First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
Sara Manglaviti, Italy
- P50.06:** Afatinib Treatment Response in Advanced Lung Adenocarcinomas Harboring Uncommon Mutations in Chinese Population
Teng Li, China
- P50.07:** Targeting HER2 or EGFR Exon 20 Insertion Mutation in Lung Cancer - A Case Series from India
Vivek Joseph Varughese, India
- P50.08:** Characteristics and Clinical Outcomes of HER2 Mutated Non-small Cell Lung Cancer Patients Detected by NGS in Routine Clinical Practice
Yejeong Han, Korea

P51: Novel Therapeutics and Targeted Therapies - EGFR Resistance

✖ NOT FOR CME CREDIT

- P51.01:** Tepotinib plus an EGFR TKI in patients with EGFR-mutant NSCLC and resistance to EGFR TKIs due to MET amplification (METamp)
Chong Kin Liam, Malaysia
- P51.02:** Stacking on the Targets: Secondary Resistant, Potential Targetable Genetic Alterations in Patients With Epidermal Growth Factor Receptor NSCLC
Nagashree Seetharamu, USA
- P51.03:** Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial
Caicun Zhou, China
- P51.04:** Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR- Mutated Non-Small Cell Lung Cancer
Hyesook Kim, Korea
- P51.05:** Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study
Sanjay Popat, UK
- P51.06:** Outcomes of First-Line TKI Treated Advanced NSCLC with Distinct Types of EGFR Mutations: Brain Metastasis and de Novo T790M
Ya Zeng, China
- P51.07:** Small Cell Transformation of Non Small Cell Lung Carcinoma: Tissue Biopsy Is Here to Stay!
Mansi Sharma, India

P52: Novel Therapeutics and Targeted Therapies - KRAS

 NOT FOR CME CREDIT

- P52.01:** Understanding Treatment Preferences of Patients With KRAS p.G12C[LC1] [MK2] – Mutated Advanced Non-Small Cell Lung Cancer
Kelley Myers, USA
- P52.02:** High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer
Hui-Bo Feng, China
- P52.03:** Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreak 100
Suresh Ramalingam, USA
- P52.04:** Histone Deacetylase 6 Inhibition Reveals Metabolic Vulnerabilities in KRAS Non-Small Cell Lung Cancer
Catriona Dowling, Ireland
- P52.05:** Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants
Jonathan Pachter, USA

P53: Novel Therapeutics and Targeted Therapies - Others

 NOT FOR CME CREDIT

-
- P53.01:** Clinical Application of NGS Technology. Therapeutic Possibilities and Future Perspectives
Silvia Sequero-Lopez, Spain
- P53.02:** Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
Alexander Drilon, USA
- P53.03:** The Characteristics of FGFR Genetic Aberrations in Chinese Lung Cancer Patients
Xiuqin Zhang, China
- P53.04:** Local Therapies vs. Specific TKIs as the Initial Treatment for Oligo-Recurrent Lung Adenocarcinoma With Driver Mutations
Yosuke Matsuura, Japan
- P53.05:** Inhibition of Tumor Cell Intrinsic Complement Regulatory Proteins Leads to Decreased Tumor Growth in a Mouse Model of NSCLC
Emily Kleczko, USA
- P53.06:** A Multi-Phase Quality Initiative to Improve Processes of Care for Non-small Cell Lung Cancer (NSCLC) in US Community Cancer Centers
Matthew Smeltzer, USA
- P53.07:** Clinical and Genomic Insights Into of Chinese Lung Cancer Patients with HER2 Amplification
Chengzhi Zhou, China
- P53.08:** Concomitant Fibrates and Immunotherapy in Non-Small Cell Lung Cancer Patients in the Veterans Health Administration
William Stokes, USA

P54: Palliative and Supportive Care

 NOT FOR CME CREDIT

- P54.01:** Analysis of the Support Needs of Lung Cancer Patients
Christie Lagogianni, UK
- P54.02:** Palliative Treatment of Tumor Stenoses of the Trachea and Bronchi
Vladyslav Severgin, Ukraine
- P54.03:** Bilateral Indwelling Pleural Catheters
Avinash Aujayeb, UK
- P54.04:** Detecting Elevated Risk of Diminished Quality of Life Among Lung Cancer Patients by Using Wearable Devices
Maria Torrente, Spain
- P54.05:** Stereotactic Radiotherapy for Brain Metastases in Patients With Lung Cancer: Cyberknife Experience
Süreyya Sarihan, Turkey
- P54.06:** The FITNESS Study: Geriatric Assessment, Treatment Toxicity, and Biospecimen Collection Among Older Adults With Lung Cancer
Madison Grogan, USA

P55: Patient Advocacy

 NOT FOR CME CREDIT

- P55.01:** Standard of Care Disparity in a Global Cancer Support Group:
Examining an Advocate Survey to Inspire Change.
Jamie Gibbard, USA
- P55.02:** Robotic Surgery in Canada: Are Patients Willing to Pay Out-of-Pocket?
Yogita S. Patel, Canada
- P55.03:** Results of The First Survey Using EORTC QLQ INFO25 on Information
Acquisition and Satisfaction of Lung Cancer Patients in Japan
Takayuki Takahama, Japan

P56: Predictive Tumor Based Assays/ Biomarkers/ Pathology - Histopathology

 NOT FOR CME CREDIT

- P56.01:** Semiquantitative Assessment of Tumor Spread Through Air Spaces in a Historic Cohort of Lung Adenocarcinomas Following Open Surgical Resection
Weiwei Shi, USA
- P56.02:** Novel Low Malignant Potential/Vascular Invasive (LMPVI) Grade is Superior to WHO 2015 and IASLC 2020 Adenocarcinoma Grade
Ilyas Yambayev, USA
- P56.03:** Prognostic Value of Tumor Spread Through Air Spaces in Patients With Lung Adenocarcinoma after Radical Surgery
Shiqi Chen, China
- P56.04:** Pathological Features & Prognosis of NSCLC Patients With Enteric Adenocarcinomas Without Expression of TTF-1 and Napsin A
Daniel Christoph, Germany
- P56.05:** Detection Rate and Prognosis of Nodal-Micro Metastasis by IHC in pN0 Resectable Non-Small Cell Lung Cancer
Sophon Siwachat, Thailand
- P56.06:** Clinical Significance and Potential Function of S100A10 in Lung Adenocarcinoma
Jiyan Dong, China

P57: Predictive Tumor Based Assays/ Biomarkers/ Pathology - ICI Biomarkers

✗ NOT FOR CME CREDIT

- P57.01:** Immunotherapy Fits Everyone? Prognostic Markers for Immune-checkpoint-Inhibitor (ICI) in Non-small Cell Lung Cancer (NSCLC)
Susana Baptista de Almeida, Portugal
- P57.02:** Integration of Systemic / Tumor PD-L1 as a Predictive Biomarker of Clinical Outcome in Advanced NSCLC Patients Treated With Anti-PD-(L)1 Agents
Margarita Majem, Spain
- P57.03:** Cellular Engagement and Interaction in the Tumor Microenvironment (TME) Predicts Response to ICI in Metastatic NSCLC
Angel Qin, USA
- P57.04:** Predicting Treatment Response to 1st- line Pembrolizumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with High PDL1 Expression
Ian Janzen, Canada
- P57.05:** Low Variant Allele Frequency of TP53 as a Biomarker for PD-1/PD-L1 Inhibitors in Lung Adenocarcinoma
Shouzheng Wang, China
- P57.06:** EGFR Mutational Status and PD-L1 in Early-Stage Brazilian Non-Small-Cell Lung Cancer
Leticia Ferro Leal, Brazil
- P57.07:** The Scottish Immunotherapy Prognostic Score (SIPS) Predicts Response to First-Line Pembrolizumab for Metastatic Non-Small Cell Lung Cancer
Mark Stares, UK
- P57.08:** High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC
Giulia Mazzaschi, Italy
- P57.09:** Common Oncogenic Driver Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer of Smokers and Never Smokers
Chong Kin Liam, Malaysia
- P57.10:** Clinicopathological Analysis of Anti-Tumor Immunology-Related Factors After Chemoradiotherapy for Lung Cancer
Misa Noguchi, Japan
- P57.11:** The Role of Serum Proteomic Signature in Predicting Survival by PD-L1 Status in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
Leeseul Kim, USA
- P57.12:** Clinical and Molecular Features of Chinese Lung Cancer Patients With Germline Mismatch Repair Gene Mutations
Jing Bai, China
- P57.13:** Correlation of TP53/KMT2C co-mutation and Tumor Microenvironment in Lung Cancer
Xuhui Zhang, China
- P57.14:** LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma
Xin Jin, China

P57.15: Safety and Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Low Creatinine Clearance Rate

Jia-Yi Deng, China

P57.16: Inflammatory Markers as Predictors of Treatment Response and Survival in Patients With Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors

Ioannis Gkiozos, Greece

P58: Predictive Tumor Based Assays/ Biomarkers/ Pathology - Predictive Biomarkers/ Pathology NOT FOR CME CREDIT**P58.01: Dysbiosis of Fecal Microbiome in Advanced Non-Small-Cell Lung Cancer**

Xueqin Chen, China

P59: Predictive Tumor Based Assays/ Biomarkers/ Pathology - Targeted Therapies Biomarkers

 NOT FOR CME CREDIT

- P59.01:** Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy
Ji Hyun Lee, Korea
- P59.02:** Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China
Wei Wu, China
- P59.03:** Comparison of Two RNA-Based Platforms for Detection of Fusions and Met Splicing Variant in Non Small Cell Lung Cancer Samples
Clara Mayo-de-las-Casas, Spain
- P59.04:** Molecular Characterization of Unactionable EGFR Mutation in Non-Small Cell Lung Cancer
HuiTa Wu, China
- P59.05:** Integration of Molecular Cancer Classification and NGS to Identify Metastatic Cancer Patients Eligible For Lung Cancer Directed Therapy
Kaushal Parikh, USA
- P59.06:** Prognostic Nutritional Index in Real-World Patients Receiving Systemic Therapy for Driver Mutation-Positive Metastatic NSCLC
Amanda Gibson, Canada
- P59.07:** Mutation Profile of BRAF in Chinese Non-Small Cell Lung Cancer Patients
Xinghao Ai, China
- P59.08:** Identifying the Origin of Lung-Specific Cancer of Unknown Primary Based on Comprehensive Genomic Profiling Optimized With DNA Methylation
Yun Fan, China
- P59.09:** Landscape of Targetable Genomic Alterations in Hispanic/ Latinx Patients With Non-Small Cell Lung Cancers
Ana Velazquez, USA
- P59.10:** A Sneak Peak in the Future World of EGFR Mutations: ML Based PFS Differences Between Del 19 and L858R
Ullas Batra, India
- P59.11:** Real-World Data of NGS Diagnostic Biomarker Testing for Lung Cancer Patients in Japan
Toshiaki Takahashi, Japan
- P59.12:** KRAS Mutation Subtypes in Non-Small Cell Lung Cancer and Clinical Outcomes: A Single Centre Experience
Alexander Davis, Australia
- P59.13:** The Prediction Performance of TP53 / RB1 Co-Mutation on Small-Cell Lung Cancer Transformation in Patients With Non-Small Cell Lung Cancer
Zaiwen Fan, China
- P59.14:** Concordance and Performance of ddPCR Compared to NGS for The Detection of KRAS G12C Mutation
Andres Cardona Zorrilla, Colombia

- P59.15:** Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)?
Inger Johanne Eide, Norway
- P59.16:** Characterizing the Tumour-Immune Microenvironment in EGFR Mutant NSCLC
Ken O'Byrne, Australia
- P59.17:** EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients
Preet Walia, Canada
- P59.18:** Evaluation of ROS1 Expression in a Large Cohort of Early Stage Lung Cancer
Anne Pernille Dyrbekk, Norway
- P59.19:** MET Alterations and Co-Drivers With Poor Prognosis in Patients With Metastatic Non-Small Cell Lung Cancer
Maritza Ramos-Ramirez, Mexico
- P59.20:** Natural History of Kras Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study
Paolo Bironzo, Italy
- P59.21:** Impact of Reflex Testing on Pathology Based Molecular Testing in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Melina Marmarelis, USA
- P59.22:** Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Real World Practice
Jose Nicolas Minatta, Argentina
- P59.23:** Biomarker Testing for Non-Small Cell Lung Cancer at a Tertiary Referral Hospital in Ireland: Challenges and Opportunities
Philip Bredin, Ireland
- P59.24:** Genomic Abnormalities in Malignant Pleural Effusion of Lung Cancer Patients Detected by Multiplex Ligation-Dependent Probe Amplification
Caroline Faria, Brazil
- P59.25:** Prognostic and Treatment Characteristics of Metastatic KRAS G12C Mutant NSCLC
Anifat Elegbede, Canada
- P59.26:** Comparison of RT-PCR, NGS and FISH/IHC Methods in Detection of Gene Fusions
Yue Pu, China
- P59.27:** Complementary Utility of Combined ALK/ROS1 FISH with Immunohistochemistry for ALK/ROS1 Rearrangement Testing in Lung Cancer
Aruna Nambirajan, India
- P59.28:** Protocol Adaptation for gDNA Extraction of FFPE Samples of Lung Adenocarcinoma Tissue and Related Mediastinal Lymph Nodes
Caroline Faria, Brazil
- P59.29:** Frequency of PIK3CA Mutations and Therapeutic Outcomes in NSCLC
Guillermo Martos, Canada

- P59.30: Genomic Landscape of Lung Cancer in the Young**
Rossana Ruiz, Peru
- P59.31: A High Number of Co-Current Genetic Alterations Is Associated With Poor Survival in EGFR Mutated Metastatic NSCLC Patients**
David Heredia, Mexico
- P59.32: Physician Attitudes Toward Genetic Testing and Targeted Therapy for Advanced NSCLC Patients in China: A Nationwide Survey**
Xiao Meng, China

P60: Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers

 NOT FOR CME CREDIT

- P60.01:** Investigation of Aurora Kinase A as a Potential Biomarker of Radiation in Non-Small Cell Lung Cancer (NSCLC)
Timothy Mitchell, UK
- P60.02:** Polymorphisms of APE1(T444G), hOGG1(C977G), XRCC1(G839A), XPD(T2251G), XPG(G3310C), XPC(A2815C) Genes in Lung Cancer Patients
Marina Bakanova, Russian Federation
- P60.03:** Transcriptome and Genome Profiles of Metastatic Lung Cancers Highlighted Predictive Power of Infection-Related Model in Metastasis
Peixin Chen, China
- P60.04:** TTF1 Expression in Advanced Lung Adenocarcinoma and Survival Outcome: An Observational Study
Rebecca Webster, Australia
- P60.05:** Radiomic Signature to Predict Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer
Martina Aineseder, Argentina
- P60.06:** Systematic Variant Profiling Delineates the Radiogenomic Landscape of Cancer
Priyanka Gopal, USA
- P60.07:** Comprehensive Genomic Profiling of Microsatellite Instability-High Lung Cancer in China
Chengzhi Zhou, China
- P60.08:** Systemic Immune-Inflammatory Index (SII) as a Biomarker for Metastatic Non-Small Cell Lung Cancer
Samia Asif, USA
- P60.09:** Real-World Readiness of US Laboratories to Test Metastatic NSCLC Patients for Rare Actionable Genomic Variants by NGS
Marieke Hoefsmit, UK
- P60.10:** A 27-Gene IO Assay to Capture the Tumor Immune Microenvironment Is Associated With Response in Metastatic and Primary Tumors
Matthew Varga, USA
- P60.11:** Trends in Molecular Testing for Metastatic Non-Small Cell Lung Cancer in The US Oncology Network Community Practices
Nicholas Robert, USA
- P60.12:** Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC
Monica Motwani, USA
- P60.13:** MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study
Makenzi Evangelist, USA

P60.14: A United States Study Focused on Patients' Understanding of, Attitudes Towards, and Barriers to the Use of Biomarker Testing for NSCLC

Upal Roy, USA

P61: Screening and Early Detection - Engagement in Lung Cancer Screening

✗ NOT FOR CME CREDIT

- P61.01:** Intelligence Assistant Million Early-Stage Lung Cancer Research Program in China
Dawei Yang, China
- P61.02:** The Use of PLCom2012 vs PLCom2012noRace Risk Prediction Models in a UK Lung Cancer Screening Programme
Patrick Bradley, UK
- P61.03:** Comparison of the Sensitivity of Different Screening Algorithms to Select Lung Cancer Patients for Screening in a Cohort of German Patients
Julia Walter, Germany
- P61.04:** Disparities Related to Low-Dose Computed Tomography Screening Eligibility Criteria for Lung Cancer: A Single-Center Analysis
Samuel Kareff, USA
- P61.05:** Time to Loosen Up: Liberalizing Lung Cancer Screening Guidelines Might Save More Lives
Coral Olazagasti, USA
- P61.06:** Participants With Family History of Cancer Have a Higher Participation Rate of Low-Dose Computed Tomography for Lung Cancer Screening
Lanwei Guo, China
- P61.07:** Advancing Health Equity in Cancer Care: The Lived Experiences of Poverty and Access to Lung Cancer Screening
Ambreen Sayani, Canada
- P61.08:** A Light Gradient Machine-Enabled Radiomics Model for Survival Prediction in Non-Small-Cell Lung Cancer-Not Otherwise Specified
Kit Yee Leung, USA
- P61.09:** Feasibility of Lung Cancer Screening With Low-Dose Computed Tomography in a Rural Community Setting; An 8-Year Experience
Jacques Townsend, USA
- P61.10:** Swiss Pilot Low-Dose Computed Tomography Lung Cancer Screening Study
Lisa Jungblut, Switzerland

P62: Screening and Early Detection - Technological Advances for Detection and Prognostication of Early-Stage Lung Cancer

 NOT FOR CME CREDIT

- P62.01:** PREVALUNG: Evaluation of Lung Cancer Prevalence in Patients With Smocking-associated Atherosclerotic Cardiovascular Diseases
David Boulate, France
- P62.02:** A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes
Julie Wu, USA
- P62.03:** Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening
Chloe Su, USA
- P62.04:** Neoteric Small Extracellular Vesicles Based Biomarker for Predicting Cancerous Sub-Solid Nodules of Lung
Nishant Patel, China
- P62.05:** Identifying Risk-Factors for Lung Cancer Diagnosis After Detection of Incidental Lung Nodules
Nicholas Faris, USA
- P62.06:** A Radiomics Nomogram for Preoperative Prediction of Occult Lymph Node Metastasis in Early-Stage Solid Lung Adenocarcinoma
Ran Zhang, China
- P62.07:** Pre-surgical Assessment of Mediastinal Lymph Node Metastases in Stage IA Non-small-cell Lung Cancers
Yeqing Zhu, USA
- P62.08:** The Non-Intrusive LuCED® Test for Detection of Early-Stage Lung Cancer: A Subgroup Analysis for Chronic Obstructive Pulmonary Disease (COPD)
Michael Meyer, USA
- P62.09:** A Prospective Cohort Evaluation of the Sensitivity and Specificity of the Chest X-Ray for the Detection of Lung Cancer in Symptomatic Adults
Nathaniel Hatton, UK
- P62.10:** AI-Based Three-Dimension Reconstruction for Pulmonary Nodules -New Auxiliary Exploration for Thoracic Surgery
Nan Wu, China
- P62.11:** Germline Genetic Testing in Patients with Lung Cancer in a Mexican Center
Guillermo Pacheco-Cuellar, Mexico

P63: Small Cell Lung Cancer/ NET - Clinical Studies

 NOT FOR CME CREDIT

- P63.01:** Lurbinectedin in Pre-Treated Patients With Small Cell Lung Cancer and Malignant Pleural Mesothelioma in a Real World Setting
Daphne Dumoulin, Netherlands
- P63.02:** Exposure-Response Analysis of Lurbinectedin Alone or With Doxorubicin in Overall Survival in Small Cell Lung Cancer
Salvador Fudio, Spain
- P63.03:** Very Limited SCLC Benefits From Surgery and Adjuvant Chemotherapy – A Large Retrospective Analysis
Diego Kauffmann-Guerrero, Germany
- P63.04:** Minimum Number of Lymph Node Dissections for Resectable Early-Stage Small Cell Lung Cancer
Takefumi Komiya, USA
- P63.05:** Treatment Pattern in Small Cell Lung Cancer: A Real-world Observational Study in the Era of Immune Checkpoint Inhibitors
Ke Zu, USA
- P63.06:** Immunotherapy Improved Pathological Response for Resectable Limited Stage Small Cell Lung Cancer- A Case Serial
Hongxia Li, China
- P63.07:** Real World Predictors for Long Term Survival in Stage IV Small Cell Lung Cancer Treated With Standard of Care Chemotherapy
David Dawe, Canada
- P63.08:** Real-World Utilization of Immune Checkpoint Inhibitors in Extensive Stage Small Cell Lung Cancer in Community Settings
Ke Zu, USA
- P63.09:** Surgical Management of Cushing's Syndrome Secondary to Lung Carcinoid Tumors: Changing Perspectives
Kenneth Seastedt, USA
- P63.10:** Safety of Simultaneously Performed Radiotherapy in Patients With Small-Cell Lung Cancer Undergoing Atezolizumab Treatment
Daniel Christoph, Germany
- P63.11:** Real-World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy
Shiven Patel, USA
- P63.12:** Radiotherapy for Small Cell Lung Cancer in Current Clinical Practice Guidelines
Haiyan Zeng, Netherlands
- P63.13:** Long Term Survival Characteristics in SCLC Patients Receiving Atezolizumab and Chemotherapy
Anifat Elegbede, Canada
- P63.14:** Three Weekly Irinotecan for Refractory/Relapsed Small Cell Lung Cancer
Snigdha Nutalapati, USA

P63.15 **Clinical Analysis of 89 Female Patients With Small Cell Lung Cancer**
Fei Teng, China

P64: Small Cell Lung Cancer/ NET - Clinical Trial in Progress

 NOT FOR CME CREDIT

- P64.01:** The Canadian Small Cell Lung Cancer Database (CASCaDe): A Multi-Institutional Real-World Evidence Collaboration
Sara Moore, Canada
- P64.02:** EMERGE 402 Phase 4 Observational Study: Safety and Outcomes in Patients With SCLC Receiving Treatment With Lurbinectedin
Raj Hanvesakul, UK
- P64.03** A Phase II Single-Arm Trial of Apatinib as Maintenance Treatment Following First-Line Chemotherapy in Extensive Stage Small Cell Lung Cancer
Fei Teng, China
- P64.04** Hypo-Fractionated Versus Conventionally Fractionated Radiotherapy for Patients with LS-SCLC: An Open-Label, Randomized, Phase 3 Trial
Nan Bi, China

P65: Small Cell Lung Cancer/ NET - Diagnostic/Imaging

 NOT FOR CME CREDIT

- P65.01:** Are Serum Markers Useful In Patients With Resected Pulmonary High-Grade Neuroendocrine Tumors?
Kazuo Nakagawa, Japan

P66: Small Cell Lung Cancer/ NET - Pre-Clinical

 NOT FOR CME CREDIT

-
- P66.01:** Characterize the Heterogeneity of the Immunophenotype in Different Neuroendocrine (NE) Subtypes of Small-Cell Lung Cancer (SCLC)
Yi Guo, China
- P66.02:** The Prognostic Implication of hes1 Protein Expression in Resected Small Cell Lung Cancers of 247 Cases
Li Liu, China
- P66.03:** The Functional Role of TGF- Signaling in SCLC Heterogeneity and Metastasis
Yujuan Jin, China
- P66.04:** A Multimodal Biomarker Predicts Dissemination of Bronchial Carcinoid
Dwayne Naves, Netherlands
- P66.05:** Correlation Between Expression of Immune Cell-Related Molecular Markers and Prognosis in Small Cell Lung Cancer (SCLC)
Yi Guo, China
- P66.06:** GPNMB Associates With Inferior Prognosis in SCLC Patients Through Promoting Tumor Cell Metastasis
Qian Liu, China
- P66.07:** ASCL1 and DLL3 Expression and Their Clinicopathological Implications in Surgically Resected Pure Small Cell Lung Cancer
Jiyan Dong, China
- P66.08:** Differential Expression of INSM1 Between Pure SCLC and LCNEC After Surgical Resection and Its Clinicopathological Significance
Li Liu, China
- P66.09:** Differential Orthopedia Homeobox (OTP) Expression in Pulmonary Carcinoids is Regulated Through Methylation
Laura Moonen, Netherlands

P67: Staging/Pulmonary Medicine

✖ NOT FOR CME CREDIT

P67.01: Cough in Patients After Thoracic Surgery: A Pilot Study

Taiyang Liuru, China

P67.02: Long-term Follow-up Data of Respiratory Function in Patients with Lung Cancer Undergoing Surgery

Ken Onodera, Japan

P68: Tumor Biology and Systems Biology: Basic and Translational Science - Advances in Lung Cancer

 NOT FOR CME CREDIT

- P68.01:** Tumor-Derived Exosomal miRNA-190b-5p Induces Microglia M2 Polarization to Promote Brain Metastasis of Lung Cancer
Wenwen Xu, China
- P68.02:** Losartan Enhances Lung Squamous Cell Carcinoma's Sensitivity to Cisplatin Treatment By Promoting Mesenchymal to Epithelial Transformation
Zenán Lin, USA
- P68.03:** An AI Workflow to Detect and Report Tumor Cell Proportion of H&E-Stained Tissue Samples
Tao Wang, China
- P68.04:** Molecular Mechanism of MK2 Promoting Lung Adenocarcinoma Progression by Phosphorylating Transcription Regulator CRABP2
Jianxiong Deng, China
- P68.05:** Human Lung Carcinoma Primary Cultures From Malignant Pleural Effusions as a Tool for Drug Screening and Personalized Therapy
Miguel Angel Molina-Vila, Spain
- P68.06:** Development and Validation of an NGS-Based MSI Detection Method
Shanshan Xiao, China
- P68.07:** Long Non-Coding RNA linc00665 Inhibits CDKN1C Expression by Binding to EZH2 and Affects Cisplatin Sensitivity of NSCLC
Zhaoxia Wang, China
- P68.08:** ERK3/MAPK6 Does Not Contribute to Cell Proliferation in NSCLC
Sofia Morazzo, Czech Republic
- P68.09:** Precision Cut Lung Slices Models for Lung Cancer Chemoprevention Investigations
Kayla Sompel, USA
- P68.10:** PFN1 Induces Tumor Metastasis Through Promoting Secretion of Microvesicles By ROCK I/p-MLC Pathway in Non-Small Cell Lung Cancer
Ya Wang, China
- P68.11:** Correlation of CD26 With Pro-Fibrotic Mediators in Lung Tumors
Wolfgang Junggraithmayr, Germany
- P68.12:** Inter-Tumor Heterogeneity of CD44 Expression in Non-Small Cell Lung Cancers / EGFR Mutated Lung Adenocarcinomas
Kenichi Suda, Japan
- P68.13:** Lung Cancer Prognosis and Cell Ratio Factors
Oleg Kshivets, Russian Federation
- P68.14:** Sensitivity to Statin in EMT-Induced NCI-H322M Cells is Further Enhanced by Simultaneous Downregulation of HMGCR Expression
Katsuhiko Warita, Japan

- P68.15: Lung Cancer in Young Patients Under 45 Years: A French Study**
Christelle Clément-Duchêne, France
- P68.16: Effect of GH / IGF1 System on Lung Cancer Cells A549**
Alejandra Ramírez-Muñoz, Mexico
- P68.17: Exosome-Mediated Transfer of SERPINE2 Regulates Non-Small Cell Lung Cancer Cells Repopulation After Ionizing Radiation**
Lucheng Zhu, China
- P68.18: Relationship Between Cholesterol Synthesis in Cancer Cells and Anticancer Effect of Statins**
Tomoko Warita, Japan

P69: Tumor Biology and Systems Biology: Basic and Translational Science - Immunology and Immunotherapy of Lung Cancer

 NOT FOR CME CREDIT

- P69.01:** The Role of the Pregnancy Associated Protein Glycodelin and Its Influence on the Immune System in Non-Small-Cell Lung Cancer
Sarah Richtmann, Germany
- P69.02:** Video-Assisted Mediastinoscopic Lymphadenectomy Improves Natural Killer Cytotoxicity in Non-Small Cell Lung Cancer
Akif Turna, Turkey
- P69.03:** Chemotherapy Upregulates PD-L1 Expression and Activates cGAS-STING Pathway in Non-Small Cell Lung Cancer Models
Maryam Khalil, Canada
- P69.04:** Immune-Related Genomic Features in Non-Small-Cell Lung Cancer
Zhaoxia Wang, China

P70: Tumor Biology and Systems Biology: Basic and Translational Science - Omics Analysis of Lung Cancer

 NOT FOR CME CREDIT

- P70.01:** KRAS G12C Mutations Among NSCLC Patients Present With a High Intraregional Variation, Indicating a Population Substructure
Andres Cardona Zorrilla, Colombia
- P70.02:** Clinicopathological and Genetic Ancestry Impact of TP53 Mutations in Brazilian Lung Adenocarcinoma Patients
Rodrigo de Oliveira Cavagna, Brazil
- P70.03:** Computational Omics Biology Model (CBM) Identifies Amplifications of Chromosome 6p to Predict Chemotherapy Resistance
Vamsidhar Velcheti, USA
- P70.04:** Results From a Patient Avatar Program Utilizing Murine Xenografts and Organoids After Neoadjuvant Therapy for Operable NSCLC
Caroline Huynh, Canada
- P70.05:** Identification of Germline Mutations in Young Never Smokers With Lung Adenocarcinoma by Whole Exome Sequencing
Yang Zhang, China
- P70.06:** m6A reader IGF2BP1 High Protein Expression level Indicates a Poor Recovery for Lung Adenocarcinoma Patients
Xuequan Wang, China
- P70.07:** Examples of Population Kinetics (PopKin) Assessments of Progression-Free (PFS) and Overall Survival (OS)
David Stewart, Canada
- P70.08:** Allelic Frequencies of Population Markers Correlate with KRAS G12C Prevalence: Considerations for Ancestries and Molecular Epidemiology
Andres Cardona Zorrilla, Colombia
- P70.09:** NOTCH1 Mutations in East Asian Patients With Non-Small-Cell Lung Cancer
Qian Wang, China
- P70.10:** Prevalence of KRAS and Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
Carlos Gil Ferreira, Brazil
- P70.11:** Prevalence and Clinicopathological Characteristics of ARID1A Mutations in East Asian Patients With Non-Small Cell Lung Cancer
Qian Wang, China
- P70.12:** NTRK Gene Fusion in Advanced Non Small Cell Lung Cancer at Pham Ngoc Thach Hospital - Viet Nam
Nguyen Lam, Vietnam
- P70.13:** Different Types of ERBB3 Mutations in Chinese Non-Small Cell Lung Cancer Patients
Qian Wang, China

- P70.14:** PRKDC Mutations Recurrently Found in Non-Small Cell Lung Cancer in East Asian Patients
Qian Wang, China
- P70.15:** Mutational Subtypes and Prognosis of East Asian Non-Small-Cell Lung Cancer Harboring NF2 Mutations
Qian Wang, China
- P70.16:** Epidemiological Study of FGFR3 Mutations Among Non-Small Cell Lung Cancer Patients in China
Qian Wang, China
- P70.17:** Molecular Characteristics and Prognosis TERT Mutations in East Asian Non-Small-Cell Lung Cancer Patients
Qian Wang, China
- P70.18:** Distribution of GNAS Mutations in Chinese Patients With Non-Small Cell Lung Cancer
Qian Wang, China
- P70.19:** Clinicopathologic Characteristics of Patients With LRP1B Mutations in Chinese Non-Small Cell Lung Cancer Patients
Qian Wang, China
- P70.20:** Impact of KRAS and Co-occurring Mutations on NSCLC Master Regulator Network as Determined by Computational Omics Biology Model.
Michael Castro, USA

P71: Tumor Biology and Systems Biology: Basic and Translational Science - Targeted Therapy of Lung Cancer

 NOT FOR CME CREDIT

- P71.01:** Targeting HSPA1A in ARID2-Deficient Lung Adenocarcinoma
Xue Wang, China
- P71.02:** Molecular and Cellular Dynamics of Drug-Tolerant Persister (DTP) Cells During Osimertinib Therapy in EGFR Mutant Lung Adenocarcinoma
Masashi Mikubo, Canada
- P71.03:** A New Combination Therapy for FGFR1-Amplified Lung Cancer
Zhang Yang, China
- P71.04:** MiR-1243 Increases Radiosensitivity in EGFR-TKI Resistant Non-Small Cell Lung Cancer Cells
Yasi Xu, China
- P71.05:** Use of a Multiscale NSCLC Tumor Heterogeneity Model to Predict Tumor Growth Under Gefitinib
Adèle L'Hostis, France